United States
Securities and Exchange Commission
Washington, D.C. 20549

Schedule 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )

Filed by the Registrant ☒

Filed by a Party other than the Registrant o

Check the appropriate box:

o Preliminary Proxy Statement

○ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☒ Definitive Proxy Statement

o Definitive Additional Materials

o Soliciting Material under §240.14a-12

Theravance Biopharma, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒ No fee required.

o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on
which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

$  

Fee paid previously with preliminary materials.

o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:
March 24, 2020

The 2020 Annual General Meeting of Theravance Biopharma, Inc. (“Annual Meeting”) will be held on April 28, 2020 at 3:00 p.m. Irish Standard Time, at the offices of Theravance Biopharma Ireland Limited, Connaught House, 1 Burlington Road, Dublin 4 Ireland. In light of the most recent guidance and ongoing response to the coronavirus pandemic, we urge you not to attend the Annual Meeting in person this year but rather vote your shares by completing, signing and returning the enclosed proxy card, or following the instructions on the enclosed proxy card to submit your proxy via telephone or on the Internet. You may listen to the Annual Meeting at https://theravance.zoom.us/j/549750907.

Details regarding the business to be conducted are described in the accompanying proxy materials. Also included is a copy of our 2019 Annual Report on Form 10-K. We encourage you to read this information carefully.

Your vote is important. We urge you to date, sign, and return your proxy card in the enclosed envelope, or vote via telephone or the Internet according to the instructions in the accompanying proxy materials, as soon as possible to ensure that your shares will be represented and voted at the Annual Meeting. Voting by proxy does not preclude you from voting in person if you choose to attend the Annual Meeting.

Thank you for your ongoing support of Theravance Biopharma.

Very truly yours,

Rick E Winningham
Chief Executive Officer and Chairman
NOTICE OF 2020 ANNUAL GENERAL MEETING

Time and Date: April 28, 2020 at 3:00 p.m. Irish Standard Time

Place: Theravance Biopharma Ireland Limited, Connaught House, 1 Burlington Road, Dublin 4 Ireland

Items of Business:

(1) To elect the following three directors to serve as Class III directors until the annual general meeting held in 2023 and until their successors are duly elected and qualified: Dean J. Mitchell, George M. Whitesides and William D. Young.

(2) To ratify the appointment of Ernst & Young LLP as Theravance Biopharma, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2020.

(3) To approve a non-binding advisory resolution regarding executive compensation.

(4) To transact such other business as may properly come before the annual general meeting or any adjournment thereof.

These items of business are more fully described in the proxy statement accompanying this notice.

Adjournments: Any action on the items of business described above may be considered at the annual general meeting at the time and on the date specified above or at any time and date to which the annual general meeting may be properly adjourned.

Record Date: You are entitled to vote if you were a shareholder of record as of the close of business on March 2, 2020.

Voting: Your vote is very important. We encourage you to read the proxy statement and vote on the Internet or by telephone or submit your proxy card as soon as possible. For specific instructions on how to vote your shares, please refer to the section entitled “Questions and Answers About Procedural Matters.”

If you have any questions regarding this information or the proxy materials, please visit our website at www.theravance.com or contact our investor relations department at (650) 808-4045.

All shareholders are invited to attend the annual general meeting in person.

By order of the board of directors,

Rick E Winningham
Chief Executive Officer and Chairman

March 24, 2020

You may attend the annual general meeting in person. However, in light of the most recent guidance and ongoing response to the coronavirus pandemic, we urge you not to attend the meeting in person this year but rather, complete, date, sign and return the enclosed proxy card, or vote via telephone or the Internet as instructed in these materials, as promptly as possible in order to ensure your representation at the annual general meeting. A return envelope (which is postage prepaid if mailed in the U.S.) is enclosed for your convenience.

Important Notice Regarding the Availability of Proxy Materials for the Annual General Meeting to be held on Tuesday, April 28, 2020:

The proxy statement and annual report are available at http://investor.theravance.com/proxy
# Table of Contents

**QUESTIONS AND ANSWERS ABOUT PROCEDURAL MATTERS**  
Annual Meeting .................................................. 2  
Share Ownership ............................................... 2  
Quorum and Voting ........................................... 3  
Shareholder Proposals and Director Nominations .............. 3  
Additional Information about the Proxy Materials ............. 7  

**PROPOSAL ONE: ELECTION OF DIRECTORS**  
General .......................................................... 10  
Nominees ....................................................... 10  
Information Regarding the Nominees and Other Directors .... 10  

**PROPOSAL TWO: RATIFICATION OF THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**  
Principal Accounting Fees and Services ...................... 17  
Pre-Approval of Audit and Non-Audit Services .................. 17  

**PROPOSAL THREE: ADVISORY VOTE ON EXECUTIVE COMPENSATION**  

**CORPORATE GOVERNANCE**  
Code of Business Conduct .................................... 20  
Director Independence ....................................... 20  
Lead Independent Director .................................... 20  
Board Committees ............................................ 21  
Considerations in Evaluating Director Nominees ............... 21  
Compensation Committee Interlocks and Insider Participation 24  
Meetings of the Board of Directors .......................... 24  
Shareholder Recommendations for Nominations to the Board of Directors 24  
Board Oversight of Risk ....................................... 25  
Director Compensation ....................................... 25  
2019 Director Compensation Table .......................... 27  
Non-Employee Director Share Ownership Guidelines .......... 27  
Hedging Policy Disclosure .................................... 27  
Shareholder Communications with the Board of Directors .... 28  

**EXECUTIVE OFFICERS**  

**EXECUTIVE COMPENSATION**  
Compensation Discussion and Analysis ....................... 32  
Compensation Committee Report ............................. 32  
2019 Summary Compensation Table .......................... 44  
2019 Grants of Plan-Based Awards ............................ 45  
Outstanding Equity Awards at 2019 Fiscal Year-End .......... 46
This proxy statement is furnished in connection with a solicitation of proxies by our board of directors for use at the 2020 Annual General Meeting (the “Annual Meeting”) to be held at 3:00 p.m. Irish Standard Time (“IST”) on April 28, 2020, and any adjournments thereof. The Annual Meeting will be held at Theravance Biopharma Ireland Limited, Connaught House, 1 Burlington Road, Dublin 4 Ireland. In light of the most recent guidance and ongoing response to the coronavirus pandemic, we urge you not to attend the meeting in person this year but rather vote your shares by completing, signing and returning the enclosed proxy card, or following the instructions on the enclosed proxy card to submit your proxy via telephone or on the Internet. You may listen to the Annual Meeting at https://theravance.zoom.us/j/549750907.

As used in this proxy statement, the terms “Theravance Biopharma,” the “Company,” “we,” “us,” and “our” mean Theravance Biopharma, Inc. and its subsidiaries unless the context indicates otherwise.

Special Note regarding Forward-Looking Statements

This proxy statement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such forward-looking statements involve substantial risks, uncertainties and assumptions. All statements in this proxy statement, other than statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, intentions, designs, expectations and objectives could be forward-looking statements. The words “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “designed,” “developed,” “drive,” “estimate,” “expect,” “goal,” “intend,” “may,” “mission,” “opportunities,” “plan,” “potential,” “predict,” “project,” “projected,” “pursue,” “represent,” “seek,” “suggest,” “should,” “target,” “will,” “would” and similar expressions (including the negatives thereof) are intended to identify forward looking statements, although not all forward looking statements contain these identifying words. These statements reflect our current views with respect to future events or our future financial performance, are based on assumptions, and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. You should not place undue reliance on our forward-looking statements. Factors that we believe could cause actual results or events to differ materially from our forward-looking statements include, but are not limited to, those discussed in “Risk Factors” in Item 1A, “Management's Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 and elsewhere in our Annual Report on Form 10-K filed on February 27, 2020. We do not assume any obligation to update any forward-looking statements for any reason, even if new information becomes available in the future.
QUESTIONS AND ANSWERS ABOUT PROCEDURAL MATTERS

Annual Meeting

Q: Why am I receiving these proxy materials?

A: Our board of directors is providing these proxy materials to you in connection with our solicitation of proxies for use at the Annual Meeting to be held on April 28, 2020 at 3:00 p.m. IST, and at any adjournment thereof, for the purpose of considering and acting upon the matters set forth herein. You may attend the Annual Meeting to vote on the proposals described in this proxy statement. However, you do not need to attend the meeting to vote your shares and, light of the most recent guidance and ongoing response to the coronavirus pandemic, we urge you not to attend the meeting in person this year. Instead, you may simply complete, sign and return the enclosed proxy card, or follow the instructions on the enclosed proxy card to submit your proxy via telephone or on the Internet. We intend to mail this proxy statement and accompanying proxy card on or about March 26, 2020 to all shareholders of record entitled to vote at the Annual Meeting.

Q: What information is contained in this proxy statement?

A: The information in this proxy statement relates to the proposals to be voted on at the Annual Meeting, the voting process, the compensation of our directors and certain of our executive officers, corporate governance, and certain other information.

Q: Where is the Annual Meeting?

A: The Annual Meeting will be held at Theravance Biopharma Ireland Limited, Connaught House, 1 Burlington Road, Dublin 4 Ireland. However, in light of the most recent guidance and ongoing response to the coronavirus pandemic, we urge you not to attend the Annual Meeting in person this year but rather vote your shares by completing, signing and returning the enclosed proxy card, or following the instructions on the enclosed proxy card to submit your proxy via telephone or on the Internet. We intend to hold a short Annual Meeting that covers only required formal business and you may listen to the Annual Meeting at https://theravance.zoom.us/j/549750907 should you desire. We will not be providing a general business update at the Annual Meeting. In addition, the date, time or location of the Annual Meeting could change due to the progression of the coronavirus pandemic.

Q: Can I attend the Annual Meeting?

A: We will hold a physical meeting, which you may attend if you were a shareholder of record or a beneficial owner as of March 2, 2020 (the "Record Date"). For admission to the Annual Meeting you must present valid picture identification such as a driver's license or passport and, if asked, provide proof of share ownership as of the Record Date. The Annual Meeting will be held at Theravance Biopharma Ireland Limited, Connaught House, 1 Burlington Road, Dublin 4 Ireland. However, you do not need to attend the Annual Meeting in order to vote your shares and, in light of the most recent guidance and ongoing response to the coronavirus pandemic, we strongly urge you to vote your shares by completing, signing and returning the enclosed proxy card, or following the instructions on the enclosed proxy card to submit your proxy via telephone or on the Internet. We intend to hold a short Annual Meeting that covers only required formal business. We will not be providing a general business update at the Annual Meeting.
Share Ownership

Q: What is the difference between holding shares as a shareholder of record and as a beneficial owner?

A: Shareholders of record—If your shares are registered directly in your name with our transfer agent, Computershare, you are considered the “shareholder of record” with respect to those shares and this notice was provided to you directly by us. As the shareholder of record, you have the right to grant your voting proxy directly to the individuals listed on the proxy card or to vote in person at the Annual Meeting.

Beneficial owners—Many Theravance Biopharma shareholders hold their shares through a bank, broker, trustee or other nominee, rather than directly in their own name. If your shares are held in a brokerage account or by a bank, trustee or another nominee, you are considered the “beneficial owner” of shares held in “street name” and a notice was forwarded to you by your bank, broker, trustee or other nominee, which is considered the shareholder of record with respect to those shares.

As the beneficial owner, you have the right to direct your bank, broker, trustee or other nominee on how to vote your shares. Beneficial owners are also invited to attend the Annual Meeting. However, since beneficial owners are not shareholders of record, you may not vote your shares in person at the Annual Meeting unless you follow your bank’s, broker’s, trustee’s or other nominee’s procedures for obtaining a legal proxy. If you request a printed copy of the proxy materials by mail, your bank, broker, trustee or other nominee will provide a voting instruction card for you to use.

Quorum and Voting

Q: How many shares must be present or represented to conduct business at the Annual Meeting?

A: A quorum is the minimum number of shares required to be present at the Annual Meeting for the meeting to be properly held under our Amended and Restated Memorandum and Articles of Association and Cayman Islands law. The presence, in person or by proxy, of members holding in aggregate not less than a majority of the shares of all voting share capital of Theravance Biopharma in issue and entitled to vote will constitute a quorum at the meeting. Except as otherwise expressly provided by the Amended and Restated Memorandum and Articles of Association or by law, the holders of ordinary shares will vote together as a single class on all matters submitted to a vote or for the consent of the shareholders of Theravance Biopharma. Each holder of ordinary shares will have the right to one vote per ordinary share. A proxy submitted by a shareholder may indicate that the shares represented by the proxy are not being voted with respect to a particular matter.

Abstentions and broker “non-votes” are counted as present and entitled to vote and are therefore included for purposes of determining whether a quorum is present at the Annual Meeting.

A broker non-vote occurs when a nominee holding shares for a beneficial owner submits a completed proxy card but does not vote on a particular proposal because the nominee does not have discretionary voting power with respect to that item and has not received instructions from the beneficial owner.

Q: Who is entitled to vote at the Annual Meeting?

A: Holders of record of our ordinary shares at the close of business on March 2, 2020, the Record Date, are entitled to receive notice of and to vote their shares at the Annual Meeting. As of the Record Date, we had 63,002,301 ordinary shares in issue. In deciding all matters at the Annual
Meeting, each holder of ordinary shares of Theravance Biopharma will be entitled to one vote per ordinary share held as of the close of business on the Record Date. We do not have cumulative voting rights for the election of directors.

Q: How can I vote my shares in person at the Annual Meeting?

A: Shares held in your name as the shareholder of record may be voted in person at the Annual Meeting. Shares held beneficially in street name may be voted in person at the Annual Meeting only if you obtain a legal proxy from the broker, trustee or other nominee that holds your shares giving you the right to vote the shares. However, in light of the most recent guidance and ongoing response to the coronavirus pandemic, we urge you not to attend the meeting in person this year but rather vote your shares by completing, signing and returning the enclosed proxy card, or following the instructions on the enclosed proxy card to submit your proxy via telephone or on the Internet.

Q: How can I vote my shares without attending the Annual Meeting?

A: Shareholder of record—If you are a shareholder of record, there are three ways to vote without attending the Annual Meeting:

- Via the Internet—You may vote by proxy via the Internet by following the instructions provided in the proxy card.
- By Telephone—You may vote by proxy by telephone by calling the toll free number found on the proxy card.
- By Mail—You may vote by proxy by filling out the proxy card and returning it in the envelope provided.

Beneficial owners—If you are a beneficial owner holding shares through a bank, broker, trustee or other nominee, please refer to the information forwarded by your bank, broker, trustee or other nominee to see which voting options are available to you.

In light of the most recent guidance and ongoing response to the coronavirus pandemic, we strongly urge you to vote your shares without attending the Annual Meeting in person.

Q: What proposals will be voted on at the Annual Meeting?

A: At the Annual Meeting, shareholders will be asked to vote:

1. To elect the three directors identified in this proxy statement to serve as Class III directors until the annual general meeting held in 2023 and until their successors are duly elected and qualified;
2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3. To approve a non-binding advisory resolution regarding executive compensation; and
4. To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.

Q: What is the voting requirement to approve each of the proposals?

A: Proposal One—An ordinary resolution, being a majority of the votes duly cast at the annual general meeting is required for the election of each director. If the number of shares voted “FOR” a director nominee exceeds the number of votes cast “AGAINST,” the nominee will be elected as a
director. You may vote "FOR," "AGAINST" or "ABSTAIN" on each of the nominees for election as director. Abstentions and broker non-votes will not affect the outcome of the Proposal, other than counting towards the quorum of the meeting.

Proposal Two—An ordinary resolution, being a majority of the votes duly cast at the annual general meeting is required to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm. If the number of shares voted "FOR" the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm exceeds the number of shares cast "AGAINST," the appointment of Ernst & Young LLP as our independent registered public accounting firm will be ratified. As with Proposal One, you may vote "FOR," "AGAINST" or "ABSTAIN." Abstentions and broker non-votes will not affect the outcome of the Proposal, other than counting towards the quorum of the meeting.

Proposal Three—An ordinary resolution, being a majority of the votes duly cast at the annual general meeting is required for the non-binding advisory resolution regarding executive compensation. You may vote "FOR," "AGAINST" or "ABSTAIN." If you "Abstain" from voting, it will have the same effect as an "Against" vote. Abstentions and broker non-votes will not affect the outcome of the Proposal, other than counting towards the quorum of the meeting. This vote is advisory, and therefore not binding on our compensation committee or board of directors. Our board of directors and our compensation committee value the opinions of our shareholders, however, and will carefully review and consider the voting results when evaluating our executive compensation programs.

Q: How does the board of directors recommend that I vote?

A: Our board of directors unanimously recommends that you vote your shares:

(1) "FOR" the nominees for election as director listed in Proposal One;
(2) "FOR" the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020 as included in Proposal Two; and
(3) "FOR" the approval of the non-binding advisory resolution regarding executive compensation as included in Proposal Three.

Q: What happens if I do not give specific voting instructions?

A: Shareholder of record—If you are a shareholder of record and you:

• Indicate when voting on the Internet or by telephone that you wish to vote as recommended by our board of directors; or
• Sign and return a proxy card without giving specific voting instructions,

then the persons named as proxy holders will vote your shares in the manner recommended by our board of directors on all matters presented in this proxy statement and as the proxy holders may determine in their discretion with respect to any other matters properly presented for a vote at the Annual Meeting.

Beneficial owners—If you are a beneficial owner of shares held in street name and do not provide the bank, broker, trustee or other nominee that holds your shares with specific voting instructions then, under applicable rules, the bank, broker, trustee or other nominee that holds your shares may generally vote on "routine" matters but cannot vote on "non-routine" matters. If the bank, broker, trustee or other nominee that holds your shares does not receive instructions from you on how to vote your shares on a non-routine matter, that bank, broker, trustee or other nominee will
inform the inspector of election that it does not have the authority to vote on this matter with respect to your shares. This is generally referred to as a “broker non-vote.”

Q: How may my bank, broker, trustee or other nominee vote my shares if I fail to provide timely directions?

A: Banks, brokers, trustees or other nominees holding ordinary shares in street name for customers are generally required to vote such shares in the manner directed by their customers. In the absence of timely directions, your bank, broker, trustee or other nominee will have discretion to vote your shares on our sole routine matter—the proposal to ratify the appointment of Ernst & Young LLP. Your bank, broker, trustee or other nominee will not have discretion to vote on (i) the election of directors or (ii) approval of the non-binding advisory resolution regarding executive compensation absent direction from you as each is a “non-routine” matter.

Please note that banks, brokers, trustees or other nominees may not vote your shares on the election of directors or on the approval of the non-binding advisory resolution regarding executive compensation in the absence of your specific instructions as to how to vote, so we encourage you to provide instructions to your bank, broker, trustee or other nominee regarding the voting of your shares.

Q: What happens if additional matters are presented at the Annual Meeting?

A: If any other matters are properly presented for consideration at the Annual Meeting, including, among other things, consideration of a motion to adjourn the Annual Meeting to another time or place (including, without limitation, for the purpose of soliciting additional proxies), the persons named in the proxy card and acting thereunder will have discretion to vote on those matters in accordance with their best judgment. We do not currently anticipate that any other matters will be raised at the Annual Meeting.

Q: Can I change or revoke my vote?

A: If you are a shareholder of record, you may change your vote by (1) filing with our Secretary, prior to your shares being voted at the Annual Meeting, a written notice of revocation or a duly executed proxy card, in either case dated later than the prior proxy card relating to the same shares, or (2) by attending the Annual Meeting and voting in person (although attendance at the Annual Meeting will not, by itself, revoke a proxy). A shareholder of record that has voted on the Internet or by telephone may also change his or her vote by later making a timely and valid Internet or telephone vote.

If you are a beneficial owner of shares held in street name, subject to any rules your bank, broker, trustee or other nominee may have, you may change your vote by submitting new voting instructions to your bank, broker, trustee or other nominee.

Any written notice of revocation or subsequent proxy card must be received by our Secretary prior to the taking of the vote at the Annual Meeting. Such written notice of revocation or subsequent proxy card should be hand delivered to our Secretary or should be sent to us care of our U.S. subsidiary, Theravance Biopharma US, Inc., at 901 Gateway Boulevard, South San Francisco, California 94080, Attention: Secretary.

In light of the most recent guidance and ongoing response to the coronavirus pandemic, we urge you not to attend the meeting in person this year but rather vote your shares by completing, signing and returning the enclosed proxy card, or following the instructions on the enclosed proxy card to submit your proxy via telephone or on the Internet. Changing your vote prior to the Annual Meeting is most easily accomplished if you submit your proxy via telephone or on the
Q: Who will bear the cost of soliciting votes for the Annual Meeting?

A: We will bear all expenses of this solicitation, including the cost of preparing and mailing these proxy materials. We may reimburse banks, brokerage firms, custodians, nominees, fiduciaries and other persons representing beneficial owners of ordinary shares for their reasonable expenses in forwarding solicitation material to such beneficial owners. Directors, officers and employees of Theravance Biopharma may also solicit proxies in person or by other means of communication. Such directors, officers and employees will not be additionally compensated but may be reimbursed for reasonable out-of-pocket expenses in connection with such solicitation. We may engage the services of a professional proxy solicitation firm to aid in the solicitation of proxies from certain shareholders. If retained, we would not expect our costs for such services to be significant.

Q: Where can I find the voting results of the Annual Meeting?

A: We intend to announce preliminary voting results at the Annual Meeting and will disclose the final results in a current report on Form 8-K within four business days after the Annual Meeting.

Shareholder Proposals and Director Nominations

Q: What is the deadline to propose actions for consideration at next year’s annual general meeting or to nominate individuals to serve as directors?

A: You may submit proposals, including director nominations, for consideration at future shareholder meetings.

Requirements for shareholder proposals to be considered for inclusion in our proxy materials—Shareholders may present proper proposals for inclusion in our proxy statement and for consideration at our next annual general meeting by submitting their proposals in writing to our Secretary in a timely manner. In order to be considered for inclusion in the proxy statement for the 2021 annual general meeting, shareholder proposals must be received at our principal executive offices no later than November 25, 2020 (that is, not less than 120 calendar days before the one year anniversary of the date this proxy statement was released to shareholders in connection with the 2020 Annual Meeting), and must otherwise comply with the requirements of Rule 14a-8 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). A copy of all notices of proposals by shareholders should also be sent to us care of our U.S. subsidiary, Theravance Biopharma US, Inc., at 901 Gateway Boulevard, South San Francisco, California 94080, Attention: Secretary.

Requirements for shareholder proposals to be brought before an annual general meeting—In addition, our Amended and Restated Memorandum and Articles of Association establish an advance notice procedure for shareholders who wish to present certain matters before an annual general meeting. In general, nominations for the election of directors may be made by (i) our board of directors or any committee thereof or (ii) any shareholder who (a) is a shareholder of record on the date of the giving of such notice and on the record date for the determination of shareholders entitled to vote at such meeting and (b) has delivered written notice to our Secretary no later than the Nomination Notice Deadline (as defined below), which notice must contain specified information concerning the nominees and concerning the shareholder proposing such nominations.

Our Amended and Restated Memorandum and Articles of Association also provide that the only business that may be conducted at an annual general meeting is business that is (i) specified in the notice of meeting (or any supplement thereto) given by or at the direction of our board of
directors (or any duly authorized committee thereof), (ii) otherwise properly brought before the annual general meeting by or at the direction of our board of directors (or any duly authorized committee thereof) or (iii) properly brought before the annual general meeting by a shareholder who has delivered written notice to our Secretary no later than the Notice Deadline (as defined below) and otherwise complied with the provisions of our Amended and Restated Memorandum and Articles of Association; provided, however, that the board of directors may, subject to Rule 14a-8 of the Exchange Act, resolve not to include any proposal for business made by a shareholder other than a proposal related to the nomination of a director made in accordance with Nomination Notice Deadline.

The “Notice Deadline” is defined as that date which is at least 45 days and not more than 75 days prior to the one year anniversary of the date on which we first mailed proxy materials for the prior year's annual general meeting. As a result, we anticipate that the Notice Deadline for the 2021 annual general meeting will be between January 9, 2021 and February 8, 2021. The “Nomination Notice Deadline” is defined as that date that is not less than 120 days and not more than 150 days prior to the meeting; provided, however, that in the event less than 130 days' notice or prior public disclosure of the date of the meeting is given or made to shareholders, notice by the shareholder to be timely must be so received not later than the close of business on the 10th day following the earlier of the day on which such notice of the date of the meeting was mailed or such public disclosure was made.

Recommendation of director candidates—You may recommend candidates to our board of directors for consideration by our nominating/corporate governance committee by following the procedures set forth below in “Corporate Governance—Shareholder Recommendations for Nominations to the Board of Directors.”

Q: How may I obtain a copy of the provisions of the Amended and Restated Memorandum and Articles of Association regarding shareholder proposals and director nominations?

A: A copy of the full text of the provisions discussed above may be obtained by writing to our Secretary. A copy of our Amended and Restated Memorandum and Articles of Association is posted on the Investor Relations portion of our website at www.theravance.com. A copy of all requests should also be sent to us care of our U.S. subsidiary, Theravance Biopharma US, Inc., at 901 Gateway Boulevard, South San Francisco, California 94080, Attention: Secretary.

Additional Information about the Proxy Materials

Q: What does it mean if multiple members of my household are shareholders but we only received one set of proxy materials in the mail?

A: We have adopted a procedure called “householding,” which the Securities and Exchange Commission (the “SEC”) has approved. Under this procedure, we deliver a single copy of the proxy materials to multiple shareholders who share the same address unless we received contrary instructions from one or more of the shareholders. This procedure reduces our printing costs, mailing costs, and fees. Shareholders who participate in householding will continue to be able to access and receive separate proxy cards. Upon written request, we will deliver promptly a separate copy of the proxy materials to any shareholder at a shared address to which we delivered a single copy of any of these documents. To receive a separate copy of the proxy materials, shareholders should send their requests to us care of our U.S. subsidiary, Theravance Biopharma US, Inc., at 901 Gateway Boulevard, South San Francisco, California 94080, Attention: Secretary. Shareholders who hold shares in street name (as described above) may contact their brokerage firm, bank, broker-dealer, trustee or other nominee to request information about householding.
Q: **What is the mailing address for Theravance Biopharma's principal executive offices?**

A: The mailing address for our principal executive office is P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. A copy of all shareholder correspondence provided to our Secretary should also be sent to us care of our U.S. subsidiary, Theravance Biopharma US, Inc., at 901 Gateway Boulevard, South San Francisco, California 94080. The telephone number at that location is (650) 808-6000.

Any written requests for additional information, copies of the proxy materials and 2019 Annual Report, notices of shareholder proposals, recommendations for candidates to our board of directors, communications to our board of directors or any other communications should be sent to the U.S. subsidiary address above.

Q: **What happens if I am in a location heavily impacted by COVID-19?**

A: In certain locations, proxy materials may not be able to be delivered to the extent requested by a shareholder or otherwise required to be delivered. On March 4, 2020, the SEC granted an exemption (the "COVID-19 Exemption"), pursuant to Section 36 of the Exchange Act, that a registrant or any other person is exempt from the requirements of the Exchange Act and the rules thereunder to furnish proxy statements, annual reports, and other soliciting materials, as applicable (the "Soliciting Materials"), and the requirements of the Exchange Act and the rules thereunder to furnish information statements and annual reports, as applicable (the "Information Materials"), where the following conditions are satisfied:

- The registrant's security holder has a mailing address located in an area where, as a result of coronavirus disease 2019 ("COVID-19"), the common carrier has suspended delivery service of the type or class customarily used by the registrant or other person making the solicitation; and
- The registrant or other person making a solicitation has made a good faith effort to furnish the Soliciting Materials to the security holder, as required by the rules applicable to the particular method of delivering Soliciting Materials to the security holder, or, in the case of Information Materials, the registrant has made a good faith effort to furnish the Information Materials to the security holder in accordance with the rules applicable to Information Materials.

To the extent applicable, we will rely on the COVID-19 Exemption. Proxy materials will be available via the Internet as otherwise described herein and we will make every reasonable effort to ensure that any shareholder affected by COVID-19 will be able to cast their votes.

**IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL GENERAL MEETING TO BE HELD ON APRIL 28, 2020.**

The proxy statement and annual report are available at http://investor.theravance.com/proxy
PROPOSAL ONE:
ELECTION OF DIRECTORS

General

Our board of directors may establish the authorized number of directors from time to time by resolution. Our board of directors is currently comprised of eleven members and, following the Annual Meeting, will be comprised of ten members, who are divided into three classes with staggered three-year terms. A director serves in office until his or her respective successor is duly elected and qualified or until his or her earlier death, resignation or removal. The classification of our board of directors may have the effect of delaying or preventing changes in our control or management. Our Amended and Restated Memorandum and Articles of Association authorize only our board of directors to fill vacancies on our board of directors created by death or resignation of a director. Any director appointed by our board of directors shall hold office for the remaining term of the class of director to which he or she is appointed and shall then be eligible for re-election. Any additional directorships resulting from an increase in the authorized number of directors would be distributed among the three classes so that, as nearly as possible, each class would consist of one-third of the authorized number of directors. Your proxy cannot be voted for a greater number of persons than the number of nominees named in this proxy statement.

Nominees

Three Class III directors have been nominated for election at the Annual Meeting each for a three-year term expiring in 2023. Upon the recommendation of our nominating/corporate governance committee, our board of directors has nominated Dean J. Mitchell, George M. Whitesides and William D. Young, each a current Class III director, for election as Class III directors. A fourth Class III director, Peter S. Ringrose, has informed us that he will not stand for reelection at the Annual Meeting and the company intends to leave the seat vacant while the nominating and corporate governance committee searches for a suitable replacement. The term of office of each person elected as director will continue until such director's term expires in 2023, and until such director's successor has been duly elected and qualified.

Information Regarding the Nominees and Other Directors

The following is a brief biography of each nominee nominated for election at the Annual Meeting and each director who will continue as a director after the Annual Meeting. Also listed below are the nominees' and directors' respective ages as of March 2, 2020. We have determined that each of these director nominees possesses the requisite communication skills, personal integrity, business judgment, ability to make independent analytical inquiries, and willingness to devote adequate time and effort necessary to serve as an effective member of the board of directors. Other specific experiences, qualifications, attributes or skills of nominees that contributed to our board's conclusion that the nominees should serve as directors are noted below.
## Nominees for Class III Directors for a Term Expiring in 2023

<table>
<thead>
<tr>
<th>Name</th>
<th>Age</th>
<th>Principal Occupation and Business Experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dean J. Mitchell</td>
<td>64</td>
<td>Dean J. Mitchell has served as a director since June 2014. Mr. Mitchell has served as Executive Chairman of the board of directors of Covis Pharma Holdings, a specialty pharmaceutical company, since August 2013. He was Chairman of PaxVax Corporation from January 2016 until its sale in October 2018 and is on the board of directors ImmunoGen Inc. since 2012 and Intrexon, Inc. since 2009. Mr. Mitchell served as President and Chief Executive Officer of Lux Biosciences, Inc., a biotechnology company focusing on the treatment of ophthalmic diseases, from July 2010 to August 2013. Prior to Lux Biosciences, he served as President and Chief Executive Officer of both Alpharma, Inc., a publicly traded specialty pharmaceutical company, from 2006 until its acquisition by King Pharmaceuticals, Inc. in 2008, and Guilford Pharmaceuticals, Inc., a publicly traded pharmaceutical company focused on oncology and acute care, from 2004 until its acquisition by MGI Pharma Inc. in 2005. From 2001 to 2004 he served in various senior executive capacities in the worldwide medicines group of Bristol-Myers Squibb Company, a pharmaceutical company. Prior to the Bristol-Myers Squibb Company, he spent 14 years at GlaxoSmithKline plc, in assignments of increasing responsibility spanning sales, marketing, general management, commercial strategy and clinical development and product strategy. Mr. Mitchell holds an M.B.A. from City University London and a B.Sc. in biology from Coventry University. We believe that Mr. Mitchell’s qualifications to serve as our director include his management experience in the pharmaceutical and biotherapeutics industries, in particular as it relates to later stage drug development and commercialization, and his experience as a President, Chief Executive Officer and board member of multiple biotechnology companies.</td>
</tr>
<tr>
<td>George M. Whitesides</td>
<td>80</td>
<td>George M. Whitesides, Ph.D., has served as a director since October 2013. Since the inception of Innoviva in 1996 until our spin-off from Innoviva in June 2014, Dr. Whitesides served as a director of Innoviva. He has been Woodford L. and Ann A. Flowers University Professor at Harvard University since 2004. From 1986 to 2004, Dr. Whitesides was Mallinckrodt Professor of Chemistry at Harvard University. From 1982 to 1991 he was a member of the Department of Chemistry at Harvard University and Chairman of the Department of Chemistry from 1986 to 1989. He was a faculty member of the Massachusetts Institute of Technology from 1964 to 1982. Dr. Whitesides was a 1998 recipient of the National Medal of Science. He is a member of the editorial boards of 15 scientific journals. He is also a member of the board of directors of Nano Terra Inc., Arsenal Biomedical, Inc., Lyra Biomedical, Inc., Diagnostics for All, Inc., Soft Robotics Inc. and Datacule, Inc. Dr. Whitesides holds a Ph.D. in Chemistry from the California Institute of Technology and a B.A. from Harvard University. Dr. Whitesides’ demonstrated leadership in his field, his knowledge of scientific matters affecting our business and his understanding of our industry contributed to our board’s conclusion that he should serve as a director.</td>
</tr>
<tr>
<td>Name</td>
<td>Age</td>
<td>Principal Occupation and Business Experience</td>
</tr>
<tr>
<td>---------------</td>
<td>-----</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>William D. Young</td>
<td>75</td>
<td>William D. Young has served as a director since October 2013 and has served as our lead independent director since April 2014. Prior to our spin-off from Innoviva in June 2014 and since April 2001, Mr. Young served as a director of Innoviva. He is a Senior Advisor of Blackstone Life Sciences (Clarus Ventures was acquired by Blackstone in 2018) since 2010. Mr. Young served from 1999 until 2009 as Chairman of the board of directors and Chief Executive Officer of Monogram Biosciences, Inc., a biotechnology company. From 1980 to 1999 Mr. Young was employed at Genentech, Inc., most recently as Chief Operating Officer, where he was responsible for all Product Development, Manufacturing and Commercial functions. Prior to joining Genentech, Mr. Young worked at Eli Lilly and Company for 14 years. Mr. Young has been Chairman of NanoString Technologies, a biotechnology company, since 2010, and of Annexon Biosciences, a biotechnology company and Clarus portfolio company, since March 2017. In addition, Mr. Young has been a member of the board of directors of Vertex Pharmaceuticals, a biopharmaceutical company, since May 2014 and is also a member of the board of directors of Praxis Precision Medicine, and SFJ Pharmaceuticals both Clarus portfolio companies. He was a member of BioMarin, Inc.'s board until October 2015 and Biogen Idec Inc.'s board of directors until June 2014, having served as a director since 1997 and as Chairman of the Board since 2010. Mr. Young is also a Trustee of Montage Health, a nonprofit company. Mr. Young received his M.B.A. from Indiana University and his B.S. in Chemical Engineering from Purdue University, and an honorary Doctorate of Engineering from Purdue University. Mr. Young was elected to The National Academy of Engineering in 1993 for his contributions to biotechnology. Mr. Young's demonstrated leadership in his field, his understanding of our industry and his senior management experience in several companies in our industry contributed to our board's conclusion that he should serve as a director.</td>
</tr>
</tbody>
</table>
## Incumbent Class I Directors Whose Term Expires in 2021

<table>
<thead>
<tr>
<th>Name</th>
<th>Age</th>
<th>Principal Occupation and Business Experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eran Broshy</td>
<td>61</td>
<td>Eran Broshy has served as a director since June 2014. Mr. Broshy has been an operating executive with Tailwind Capital, a New York based private equity firm, supporting their healthcare investment efforts since September 2015. From March 2013 until August 2015, he worked with Linden Capital Partners and Court Square Capital, both private equity firms, as operating partner and executive advisor, respectively, and from June 2009 until December 2012 he worked with Providence Equity Partners as a senior advisor supporting the private equity firm's healthcare information investment efforts. Mr. Broshy previously served for over a decade as the chief executive officer (until 2008) and chairman of the board of directors (until 2010) of inVentiv Health, Inc., a Nasdaq listed company (now part of Syneos Health) that delivers a broad range of clinical and commercialization services to pharmaceutical and life sciences companies globally. Prior to joining inVentiv, Mr. Broshy was a management consultant with The Boston Consulting Group (BCG) for 14 years, including as the partner responsible for BCG's healthcare practice across the Americas. He also served as president and chief executive officer of Coelacanth Corporation, a privately held biotechnology company. Within the previous five years Mr. Broshy has served on the board of directors of Magellan Health, Inc., a public specialty health care management company. He currently serves as chairman of the board of ERT and of DermaRite, both privately-held healthcare companies, as a member of the Corporation of the Massachusetts Institute of Technology (&quot;MIT&quot;), as a member of the board of governors of the American Jewish Committee, and as chairman of the board of the American Friends of the Open University of Israel. Mr. Broshy holds an M.B.A. from Harvard University, an M.S. in civil engineering from Stanford University, and a B.S. in civil engineering from the Massachusetts Institute of Technology. Mr. Broshy’s demonstrated leadership in the healthcare industry in general and the managed healthcare industry in particular contributed to our board's conclusion that he should serve as a director.</td>
</tr>
<tr>
<td>Laurie Smaldone Alsup</td>
<td>66</td>
<td>Laurie Smaldone Alsup, M.D. has served as a director since February 2018. Dr. Smaldone Alsup is Chief Medical and Chief Scientific Officer of NDA Group, a regulatory and product development consultancy firm, a position she has held since March 2016, when NDA Group merged with PharmApprove, LLC. Dr. Smaldone Alsup served as President and Chief Scientific Officer of PharmApprove, LLC, a regulatory communications consultancy firm and division of Taft and Partner, from August 2011 to March 2016. Dr. Smaldone Alsup served in clinical and regulatory roles of increasing responsibility and scope while at Bristol Myers Squibb, including Senior Vice President of Global Regulatory Science and Vice President of Corporate Strategy and Business Risk Management. In addition, she served as Chief Executive Officer of Phytomedics, Inc., an early stage company focused on arthritis and inflammation. Dr. Smaldone Alsup is a member of the board of directors of BlackBerry Limited, a cybersecurity software and services company, a position she has held since June 2015 and Arvinas, Inc., a biotechnology company, a position she has held since November 2019. Dr. Smaldone Alsup was a member of the board of directors of KaloBios Pharmaceuticals, Inc., a biotechnology company, from October 2013 to November 2015. Dr. Smaldone Alsup received a B.A. in biology from Fordham College and an M.D. at Yale University School of Medicine, where she completed her residency in Internal Medicine and fellowship in Medical Oncology. Dr. Smaldone Alsup's extensive regulatory and clinical experience in the life sciences industry, senior management experience in several companies in our industry and demonstrated leadership in her field contributed to our board's conclusion that she should serve as a director.</td>
</tr>
<tr>
<td>Name</td>
<td>Age</td>
<td>Principal Occupation and Business Experience</td>
</tr>
<tr>
<td>--------------------</td>
<td>-----</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Burton G. Malkiel</td>
<td>87</td>
<td>Burton G. Malkiel, Ph.D., has served as a director since October 2013. Prior to our spin-off from Innoviva, Inc. (&quot;Innoviva&quot;) in June 2014 and since July 2007, Dr. Malkiel served as a director of Innoviva. Dr. Malkiel is the Chief Investment Officer and chair of the Investment Committee at Wealthfront, Inc., a private investment company, a position he has held since November 2012, and the Chemical Bank Chairman's Professor of Economics, Emeritus, and Senior Economist at Princeton University, a position he has held since July 2011 following positions as a senior research economist and professor at Princeton University since 1988. Dr. Malkiel is the author of A Random Walk Down Wall Street and over 125 articles and is the author or co-author of nine other books. From 1981 to 1988 he was dean of the Yale University School of Management and also served as the William S. Beinecke Professor of Management Studies. He is a past appointee to the President's Council of Economic Advisors. In addition, Dr. Malkiel currently serves on the board of directors of several corporations including Genmab AS and served on the board of directors of The Vanguard Group Ltd. until March 2015. He also serves on several investment management boards including the Investment Committees for the American Philosophical Association and Alpha Shares, LLC. He is a past president of the American Finance Association and the International Atlantic Economic Association. He holds a B.A. and M.B.A. degree from Harvard University and a Ph.D. degree from Princeton University. Dr. Malkiel's demonstrated leadership in his field, his knowledge of financial and financing matters, and his ability to serve as a financial expert on our audit committee contributed to our board's conclusion that he should serve as a director.</td>
</tr>
<tr>
<td>Name</td>
<td>Age</td>
<td>Principal Occupation and Business Experience</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-----</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Rick E Winningham</td>
<td>60</td>
<td>Rick E Winningham has served as Chairman of the board of directors since July 2013. He has served as our Chief Executive Officer since our spin-off from Innoviva in June 2014. From October 2001 to August 2014, Mr. Winningham served as Chief Executive Officer of Innoviva, where he also served as Chairman of the board of directors from April 2010 to October 2014. From 1997 to 2001 he served as President, Bristol Myers Squibb Oncology/Immunology/Oncology Therapeutics Network (OTN) and also as President of Global Marketing from 2000 to 2001. In addition to operating responsibility for U.S. Oncology/Immunology/OTN at Bristol Myers Squibb (BMS), Mr. Winningham also had full responsibility for Global Marketing in the Cardiovascular, Infectious Disease, Immunology, Oncology/Metabolics and GU/GI/Neuroscience therapeutic areas. Over a fifteen year period beginning in 1986 with BMS and its predecessor, Bristol Myers, Mr. Winningham held various U.S. and global management positions. Mr. Winningham is a member of Biotechnology Industry Organization's board of directors and serves on the Health Section Governing Board Standing Committee on Reimbursement. Mr. Winningham served as a Director on the board of directors of the California Healthcare Institute (&quot;CHI&quot;) from November 2011 to March 2015. He was elected Chairman of CHI in January 2014, a position he held until CHI merged with BayBio to become the California Life Sciences Association (&quot;CLSA&quot;) in March 2015. Mr. Winningham is on the board of directors of Jazz Pharmaceuticals plc. and served as a member of the board of directors of OncoMed Pharmaceuticals, Inc. from June 2015 until April 2019. Mr. Winningham holds an M.B.A. from Texas Christian University and a B.S. degree from Southern Illinois University. We believe that it is appropriate and desirable for our Chief Executive Officer to serve on our board of directors. Mr. Winningham's demonstrated leadership in his field, his prior senior management experience in our industry and his experience as our Chief Executive Officer contributed to our board's conclusion that he should serve as a director.</td>
</tr>
<tr>
<td>Robert V. Gunderson, Jr.</td>
<td>68</td>
<td>Robert V. Gunderson, Jr. has served as a director since October 2013. Prior to our spin-off from Innoviva in June 2014 and since September 1999, Mr. Gunderson served as a director of Innoviva. He is a founding partner of the law firm of Gunderson Dettmer Stough Villeneuve Franklin &amp; Hachigian, LLP, where he has practiced since 1995. Mr. Gunderson is a Fellow of the American College of Governance Counsel and a Fellow of the American Bar Foundation. Mr. Gunderson served on the board of directors of Vitae Pharmaceuticals, Inc. until its sale to Allergan plc in October 2016. Mr. Gunderson holds a J.D. from the University of Chicago, where he was Executive Editor of The University of Chicago Law Review and is currently a member of the Law School Council. Mr. Gunderson also received an M.B.A. in Finance from The Wharton School, University of Pennsylvania and an M.A. from Stanford University. Mr. Gunderson's demonstrated leadership in his field, his understanding of our industry and his knowledge of financial and financing matters contributed to our board's conclusion that he should serve as a director.</td>
</tr>
</tbody>
</table>
Susan M. Molineaux, Ph.D. has served as a director since April 2015. Dr. Molineaux has served as President, Chief Executive Officer and as a member of the board of directors of Calithera Biosciences, Inc. since she co-founded the biopharmaceutical company in March 2010. Dr. Molineaux co-founded Proteolix, Inc., a biopharmaceutical company, where she served as Chief Scientific Officer from 2003 to 2005, Chief Executive Officer from January 2006 to January 2009 and again as Chief Scientific Officer from February 2009 until Proteolix's acquisition by Onyx Pharmaceuticals, Inc. in November 2009. From 2000 to 2003, Dr. Molineaux served as Vice President of Biology at Rigel Pharmaceuticals, Inc., a drug development company. From 1999 to 2000, she served as Vice President of Biology at Praelix, Inc., a biopharmaceutical company, and from 1994 through 1999, she served as Vice President of Drug Development at Praecis Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 until 1994, she was a scientist in the Immunogen group at Merck & Co. Dr. Molineaux also serves as a member of the board of directors of Geron Corporation, a biopharmaceutical company and served as a member of the board of directors of the California Life Sciences Association until March 2016. In June 2017, Dr. Molineaux joined the board of trustees of Smith College. She is also a Scientific Advisor at Lightstone Ventures. Dr. Molineaux holds a B.S. in Biology from Smith College and a Ph.D. in Molecular Biology from Johns Hopkins University, and she completed a postdoctoral fellowship at Columbia University. Dr. Molineaux's extensive management experience in pharmaceutical drug development, particularly as it relates to managing and conducting clinical trials, her experience as a Chief Executive Officer and board member of multiple biotechnology companies and her demonstrated leadership in our field contributed to our board's conclusion that she should serve as a director.

Donal O'Connor has served as a director since October 2015. Mr. O'Connor is the Chairman of Galco Steel Limited and Huttonread Unlimited Company, having been appointed to their boards in September 2010 and March 2011, respectively, and has been a non-executive Director of Perrigo Company plc since November 2014. He was the Chairman of Malin Corporation plc from July 2017 until July 16, 2018. He was a non-executive Director of Elan Corporation, plc, from May 2008 until it was acquired by Perrigo in December 2013. He was a non-executive Director and senior independent director of Readymix plc from December 2008 until May 2012. He was appointed by the Irish Government as Chairman of Anglo Irish Bank from December 2008 until June 2010. He was the Irish High Court appointed Administrator of Icarom plc from 1995 until February 2013. Mr. O'Connor was a member of the Board of the Irish Auditing and Accountancy Supervisory Authority from its inception as an Interim Board in 2001 until 2009. He was a member of PricewaterhouseCoopers' (“PwC”) Global Board from 2003 until 2008 and is a former Chairman of the PwC Eurofirms Board. Mr. O'Connor originally joined PwC in 1972 and was appointed partner in 1983. He was later appointed partner in charge of the PwC Financial Services practice in 1988 and leader of the Audit Practice in 1992. He was elected Senior Partner in 1994 and was re-elected in 1998 and 2003. He served as Senior Partner of PwC Ireland for over twelve years until 2007. Mr. O'Connor obtained a Bachelor of Commerce degree from University College Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland. Mr. O'Connor's senior management experience and demonstrated leadership in his field, his experience as a director of numerous companies, including Irish entities, and his knowledge of financial and financing matters contributed to our board's conclusion that he should serve as a director.

There are no family relationships among any of our directors or executive officers. See “Corporate Governance” below for additional information regarding our board of directors.

**OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE "FOR" EACH OF THE CLASS III NOMINEES NAMED ABOVE.**
PROPOSAL TWO:
RATIFICATION OF THE APPOINTMENT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Our audit committee has appointed the firm of Ernst & Young LLP, independent registered public accounting firm, to audit our financial statements for the year ending December 31, 2020.

Notwithstanding its selection and even if our shareholders ratify the selection, our audit committee, in its discretion, may appoint another independent registered public accounting firm at any time during the year if the audit committee believes that such a change would be in the best interests of Theravance Biopharma and its shareholders. At the Annual Meeting, the shareholders are being asked to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2020. Our audit committee is submitting the selection of Ernst & Young LLP to our shareholders because we value our shareholders' views on our independent registered public accounting firm and as a matter of good corporate governance. Representatives of Ernst & Young LLP will attend the Annual Meeting and they will have an opportunity to make statements and will be available to respond to appropriate questions from shareholders.

If this proposal does not receive the affirmative approval of a majority of the votes cast on the proposal, the audit committee would reconsider the appointment.

Principal Accounting Fees and Services

The following table sets forth all fees for invoices received or accrued by us for professional audit services and other services rendered by Ernst & Young LLP during the years ended December 31, 2018 and 2019.

<table>
<thead>
<tr>
<th>Description</th>
<th>Year Ended December 31</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2019 (in thousands)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Audit Fees(1)</td>
<td>$1,567</td>
</tr>
<tr>
<td>Audit-Related Fees</td>
<td></td>
</tr>
<tr>
<td>Tax Fees(2)</td>
<td>628</td>
</tr>
<tr>
<td>All Other Fees(3)</td>
<td>4</td>
</tr>
<tr>
<td>Total Fees</td>
<td>$2,199</td>
</tr>
</tbody>
</table>

(1) For the years ended December 31, 2018 and 2019, this category represents fees for professional services provided in connection with the audit of our financial statements, review of our quarterly financial statements, and audit services provided in connection with other regulatory filings for which only the independent registered public accounting firm can reasonably be expected to provide.

(2) For the years ended December 31, 2018 and 2019, this category represents fees related to tax consulting and planning services.

(3) For the years ended December 31, 2018 and 2019, this category represents subscription fees for online research tools.
Pre-Approval of Audit and Non-Audit Services

Consistent with requirements of the Securities Exchange Act, applicable SEC rules and the Public Company Accounting Oversight Board regarding auditor independence, our audit committee is responsible for the appointment, compensation and oversight of the work of our independent registered public accounting firm. In recognition of this responsibility, our audit committee (or the chair if such approval is needed on a time urgent basis) pre-approves all audit and permissible non-audit services provided by the independent registered public accounting firm. These services may include audit services, audit-related services, tax services and other services.

OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE "FOR" RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
PROPOSAL THREE:
ADVISORY VOTE ON EXECUTIVE COMPENSATION

The Exchange Act gives shareholders the right to vote to approve, on an advisory basis, the compensation of our named executive officers. This is commonly referred to as a "Say On Pay" proposal.

This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies and practices described in this proxy statement. As described further in the "Executive Compensation" section of this proxy statement, beginning on page 32, including the "Compensation Discussion and Analysis" and the related tables and narrative, the primary goals of our compensation programs are to fairly compensate employees, attract and retain highly qualified employees, motivate the performance of our employees towards key corporate goals, reward the achievement of such goals, and align our employees’ long-term interests with those of our shareholders. We believe our complete compensation programs reflect a pay-for-performance philosophy that links potential significant compensatory rewards to achievement of corporate operating goals and increase in shareholder value.

In accordance with Section 14A of the Exchange Act, we are asking shareholders to vote on the following resolution:

"RESOLVED, that the Company's shareholders approve the compensation of the Company's named executive officers as disclosed in the Compensation Discussion and Analysis, the 2019 Summary Compensation Table and the accompanying tables and narrative."

This Say On Pay vote is advisory, and therefore not binding on our compensation committee or board of directors. Our board of directors and our compensation committee value the opinions of our shareholders, however, and will carefully review and consider the voting results when evaluating our executive compensation programs.

CORPORATE GOVERNANCE

Code of Business Conduct

Our board of directors has adopted a code of business conduct that applies to all of our employees, officers and directors, including our Chief Executive Officer, Chief Financial Officer, and other executive and senior financial officers. The full text of our code of business conduct is posted on the Investor Relations portion of our website at www.theravance.com. We intend to disclose future amendments to, or waiver of, our code of business conduct, at the same location on our website identified above.

Director Independence

Our ordinary shares are listed on The Nasdaq Global Market. The listing rules of this stock exchange generally require that a majority of the members of a listed company's board of directors be independent. In addition, the rules of Nasdaq require that, subject to specified exceptions, each member of a listed company's audit, compensation, and nominating/corporate governance committees be independent. Under the Nasdaq rules, a director will only qualify as an “independent director” if, in the opinion of that company's board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

Audit committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Securities Exchange Act. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: (1) accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries; or (2) be an affiliated person of the listed company or any of its subsidiaries.

Compensation committee members must also satisfy the independence criteria set forth under the Nasdaq rules. In order for a member of a listed company's compensation committee to be considered independent for purposes of the Nasdaq rules, the listed company's board of directors must consider all factors specifically relevant to determine whether a director has a relationship to the company which is material to that director's ability to be independent from management in connection with the duties of a compensation committee member, including but not limited to: (1) the source of compensation of such director, including any consulting, advisory or other compensatory fee paid by the company to such director; and (2) whether such director is affiliated with the company, a subsidiary of the company or an affiliate of a subsidiary of the company.

Our board of directors has undertaken a review of the independence of each director. In making this determination, our board of directors considered the relationships that each non-employee director has with us and all other facts and circumstances that our board of directors deemed relevant in determining their independence. Based on this review, our board of directors has determined that all of our directors other than Mr. Winningham are “independent” as that term is defined under the Nasdaq for purposes of serving on our board of directors and those committees of our board of directors upon which each such director sits. The independent members of our board of directors hold, and will continue to hold, separate regularly scheduled executive session meetings at which only independent directors are present.

Lead Independent Director

Mr. Winningham serves as our chairman of the board of directors and our principal executive officer. Mr. Young serves as our lead independent director. In his role as lead independent director, Mr. Young provides a source of leadership for the board of directors that is complementary to that of Mr. Winningham as chairman of the board of directors and helps to ensure the effective independent
functioning of the board of directors in its oversight responsibilities. As the lead independent director, Mr. Young coordinates the activities of the other independent directors, including coordinating with the chairman to determine an appropriate schedule of board of directors and committee meetings, working with the chairman to schedule any special update meetings he may determine would benefit the board of directors, working with the chairman to jointly set and agree upon the agenda for meetings of the board of directors, coordinating with the chairman on the quality, quantity and timeliness of information submitted by management to independent directors, developing agendas for and serving as chairman of the executive sessions of the board of directors' independent directors, calling any special meetings of the independent directors, serving as the principal liaison between the independent directors and the chairman, coordinating with the General Counsel and Secretary responses to questions and/or concerns from shareholders, employees, or other interested parties, and, in his dual role as lead independent director and chairman of the compensation committee, delivering the results of the chief executive officer's performance evaluation. Our board believes that the combined role of chairman and chief executive officer, while balanced with our use of a lead independent director, facilitates centralized board leadership in one person, so there is no ambiguity about accountability. In addition, given the relatively small size of our company, our board of directors believes that Mr. Winningham's leadership as both chairman and chief executive officer is appropriate. Our Board of Directors Guidelines on Significant Corporate Governance Issues ("Corporate Governance Guidelines") are posted on the Investor Relations portion of our website at www.theravance.com.

Board Committees

Our board of directors has established an audit committee, a compensation committee and a nominating/corporate governance committee. Our board of directors and its committees set schedules for meetings throughout the year and can also hold special meetings and act by written resolutions from time to time, as appropriate. Our board of directors has delegated various responsibilities and authority to its committees as generally described below. The committees regularly report on their activities and actions to the full board of directors. Each member of each of our compensation, nominating/corporate governance and audit committees qualifies as an independent director in accordance with Nasdaq listing standards. Each committee of our board of directors has a written charter approved by our board of directors. Copies of each charter are posted on the Investor Relations portion of our website at www.theravance.com.

Audit Committee

The current members of our audit committee are Dr. Malkiel, Mr. Mitchell, Mr. Brosby and Mr. O'Connor, each of whom is a non-employee member of our board of directors and can read and understand fundamental financial statements. Dr. Malkiel has served as a member of the committee since October 2013, Mr. Mitchell has served since October 2014, Mr. Brosby has served since April 2015 and Mr. O'Connor has served since October 2015. Dr. Malkiel, Mr. Mitchell, Mr. Brosby and Mr. O'Connor are each independent under the rules and regulations of the SEC and the listing standards of the Nasdaq applicable to audit committee members. Dr. Malkiel serves as chair of the audit committee. Our board of directors has determined that Dr. Malkiel qualifies as an audit committee financial expert within the meaning of SEC regulations and meets the financial sophistication requirements of Nasdaq. During our fiscal year ended December 31, 2019, our audit committee held seven meetings.

The audit committee of our board of directors oversees our accounting practices, system of internal controls, audit processes and financial reporting processes. Among other things, our audit committee is responsible for periodically reviewing financial reporting processes and disclosure controls and processes based on consultation with the Company's management and independent auditors and counsel and reviewing with management and the independent auditors the adequacy and effectiveness
of the Company's internal controls over financial reporting and the effectiveness of the Company's disclosure controls and procedures. It also discusses the scope and results of the audit with our independent registered public accounting firm, reviews with our management and our independent registered public accounting firm our interim and year-end operating results and, as appropriate, initiates inquiries into aspects of our financial affairs. Our audit committee is responsible for establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters, and for the confidential, anonymous submission by our employees of concerns regarding questionable accounting or auditing matters. In addition, our audit committee has sole and direct responsibility for the appointment, retention, compensation and oversight of the work of our independent registered public accounting firm, including approving services and fee arrangements. Significant related party transactions will be approved by our audit committee before we enter into them, as required by applicable rules and listing standards.

Compensation Committee

The current members of our compensation committee are Messrs. Young and Brosky and Drs. Ringrose and Whitesides, each of whom is independent under applicable requirements of Nasdaq. Mr. Young and Drs. Ringrose and Whitesides have served as members of the committee since October 2013 and Mr. Brosky has served as a member of the committee since October 2014. Dr. Ringrose will no longer serve on the Compensation Committee after the Annual Meeting, as his term as a Board member will expire. Mr. Young serves as chair of the compensation committee. The purpose of our compensation committee is to review and approve our overall compensation strategy and policies. Specifically, our compensation committee reviews and approves corporate performance goals and objectives relevant to the compensation of our executive officers and other senior management; reviews and approves the compensation and other terms of employment of our principal executive officer and other executive officers; approves the individual bonus programs in effect for our principal executive officer, other executive officers and any key employees for each fiscal year; recommends to our board of directors the compensation of our directors; recommends to our board of directors the adoption or amendment of equity and cash incentive plans and approves the adoption of and amendments to these plans; grants options and other equity awards; and administers our equity incentive plans and similar programs. During our fiscal year ended December 31, 2019, our compensation committee held four meetings and acted once by written consent.

Mr. Winningham, our principal executive officer, does not participate in the determination of his own compensation or the compensation of our directors. However, he makes recommendations to our compensation committee regarding the amount and form of the compensation of the other executive officers and any key employees, and he often participates in the committee's deliberations about their compensation. Our General Counsel, Chief Financial Officer and our Senior Vice President, Human Resources, also assist our compensation committee in its executive officer, director and employee compensation deliberations. No other executive officers participate in the determination of the amount or form of the compensation of our executive officers or directors.

During our fiscal year ended December 31, 2019, our compensation committee engaged the services of Frederic W. Cook & Co. (“FW Cook”), a compensation consulting firm, to advise the compensation committee regarding the amount and types of compensation that we provide to our executives and directors and how our compensation practices compare to the compensation practices of other companies. FW Cook reports directly to the compensation committee. FW Cook does not provide any services to us other than the services provided to the compensation committee. The compensation committee has assessed the independence of FW Cook pursuant to SEC rules and Nasdaq listing standards and concluded that no conflict of interest exists that would prevent FW Cook from independently representing the committee.
Nominating/Corporate Governance Committee

The current members of our nominating/corporate governance committee are Drs. Malkiel, Molineaux and Smaldone Alsup and Mr. Young, each of whom is a non-employee member of our board of directors and is independent under applicable requirements of Nasdaq. Dr. Molineaux has served as chair of the nominating/corporate governance committee since she joined the committee in February 2018. Dr. Malkiel and Mr. Young have served as members of the committee since October 2013 and Dr. Smaldone Alsup has served as a member of the committee since October 2019. The nominating/corporate governance committee oversees the nomination of directors, including, among other things, identifying, evaluating and making recommendations of nominees to our board of directors, and evaluates the performance of our board of directors and individual directors. Our nominating/corporate governance committee is also responsible for reviewing developments in corporate governance practices, evaluating the adequacy of our governance practices and making recommendations to our board of directors concerning corporate governance matters. During our fiscal year ended December 31, 2019, our nominating/corporate governance committee held three meetings.

Considerations in Evaluating Director Nominees

Our nominating/corporate governance committee's criteria and process for evaluating and identifying the candidates that it selects, or recommends to the full board of directors for selection, as director nominees are as follows:

- Our nominating/corporate governance committee evaluates the current composition and organization of the board of directors and its committees, determines future requirements and makes recommendations to the board of directors for approval.

- Our nominating/corporate governance committee evaluates the performance of the board of directors and of individual directors and oversees the board of directors' performance evaluation process, including conducting surveys of director observations, suggestions and preferences.

- While our nominating/corporate governance committee has not established specific minimum qualifications for director candidates, in its evaluation of director candidates, including the members of the Board eligible for re-election, our nominating/corporate governance committee considers: (1) the current size and composition of the board of directors and the needs of the board of directors and its committees; (2) such factors as personal integrity, knowledge, skills, expertise, diversity of experience, ability to take independent analytical inquiries, understanding of Theravance Biopharma's business environment and willingness to devote adequate time and effort to serve as members of the board of directors; (3) relationships between directors and Theravance Biopharma's customers and suppliers; and (4) such other factors as the committee may consider appropriate.

- With regard to candidates who are properly recommended by shareholders or by other means, our nominating/corporate governance committee will review the qualifications of any such candidate, which review may, in our nominating/corporate governance committee's discretion, include interviewing references, direct interviews with the candidate, or other actions our nominating/corporate governance committee deems necessary or proper.

- Our nominating/corporate governance committee has the authority to retain and terminate any third-party search firm to identify director candidates, and has the authority to approve the fees and retention terms of such search firm.

- After completing its review and evaluation of director candidates, our nominating/corporate governance committee selects, or recommends to the full board of directors for selection, the director nominees.
Our nominating/corporate governance committee does not have a formal written policy with regard to the consideration of diversity in identifying director nominees. However, as discussed above, diversity of experience is one of the numerous criteria our nominating/corporate governance committee reviews before recommending a candidate.

In addition, the board of directors (which includes our Chief Executive Officer) has used and may in the future use the services of a third party search firm to help identify, screen, conduct background investigations of, and interview potential director candidates.

Compensation Committee Interlocks and Insider Participation

As noted above, the compensation committee of our board of directors is currently comprised of Messrs. Broshy and Young and Drs. Ringrose and Whitesides. None of the members of our compensation committee was at any time during the fiscal year ended December 31, 2019 (or at any other time) an officer or employee of Theravance Biopharma. None of our executive officers serve, or served during our fiscal year ended December 31, 2019, as a member of the board of directors or compensation committee of any other entity that has or has had one or more executive officers serving as a member of our board of directors or our compensation committee.

Meetings of the Board of Directors

The full board of directors met six times during our fiscal year ended December 31, 2019. During our fiscal year ended December 31, 2019 Dr. Whitesides attended fewer than 75% of the total number of meetings of the board of directors (held during the period he was a director) and fewer than 75% of the total number of meetings of the compensation committee (held during the period he was a member).

It is our policy that directors are invited and encouraged to attend our annual general meetings, and all of our directors attended the 2019 Annual Meeting. We have scheduled our Annual Meeting on the same day as a regularly scheduled board of directors meeting in order to facilitate attendance by the members of our board of directors.

Shareholder Recommendations for Nominations to the Board of Directors

Our nominating/corporate governance committee reviews shareholder recommendations for candidates to our board of directors in accordance with our Corporate Governance Guidelines and our Shareholder—Director Communications Policy & Procedures. The board of directors’ policy is to consider all bona fide director candidates recommended by shareholders. To recommend a candidate for election to the board of directors, a shareholder must notify the nominating/corporate governance committee by writing to the General Counsel or Secretary of Theravance Biopharma (Theravance Biopharma, Inc., c/o of its U.S. subsidiary, Theravance Biopharma US, Inc., at 901 Gateway Boulevard, South San Francisco, California 94080, Attention: General Counsel/Secretary) no later than the deadlines set forth in Theravance Biopharma's proxy statement for the preceding annual general meeting. Such shareholder's notice must include the following information to be considered: (i) to the extent reasonably available, information relating to such director candidate that would be required to be disclosed in a proxy statement pursuant to Regulation 14A under the Securities Exchange Act, in which such individual is a nominee for election to the board of directors, including the candidate's name, age, detailed biographical data and qualifications for serving on our board of directors (including the candidate's principal occupation or employment), information regarding any relationships between us and the candidate within the last three years and the number of our ordinary shares beneficially owned by the candidate; (ii) the director candidate's written consent to (A) if selected, be named in Theravance Biopharma's proxy statement and proxy and (B) if elected, to serve on the board of directors; (iii) a statement from the recommending shareholder in support of the candidate, including a
statement regarding the candidate's satisfaction of the board of directors' membership criteria set forth in our Corporate Governance Guidelines; and (iv) any other information that such shareholder believes is relevant in considering the director candidate. The shareholder is also advised to provide evidence of the recommending person's ownership of our shares and the shareholder's name and address.

**Board Oversight of Risk**

One of the key functions of our board of directors is informed oversight of our risk management process. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure. Our executive officers are responsible for the day-to-day management of the material risks we face. While our board of directors is ultimately responsible for risk oversight, our board committees assist the board in fulfilling its oversight responsibilities in certain areas of risk. The audit committee assists our board of directors in fulfilling its oversight responsibilities with respect to risk management in the areas of internal control over financial reporting and disclosure controls and related procedures, legal and regulatory compliance, and discusses with management and the independent auditor guidelines and policies with respect to risk assessment and risk management. The nominating and corporate governance committee assists our board in fulfilling its oversight responsibilities with respect to the management of risk associated with board organization, membership and structure, and corporate governance. The compensation committee assesses risks created by the incentives inherent in our compensation policies. Finally, the full board of directors reviews strategic and operational risk in the context of reports from the management team, receives reports on all significant committee activities, and evaluates the risks inherent in significant transactions.

**Director Compensation**

The following is a description of the standard compensation arrangements under which our non-employee directors are compensated for their service as directors, including as members of the various committees of our board of directors.

**Cash Compensation**

Each non-employee member of our board of directors receives an annual retainer of $55,000 per year. Each non-employee member of our board of directors also receives the following meeting fees: (i) $1,000 for each board meeting attended ($500 for scheduled in-person meetings that a board member attends by video or telephone conference); (ii) an additional $1,500 for attending in-person board of directors meetings held outside the United States; and (iii) $2,000 for each committee and subsidiary board meeting attended (and $1,000 for scheduled in-person meetings that a board member attends by video or telephone conference). We also pay the following fixed annual retainers to our committee chairpersons and our lead independent director:

- Lead independent director: $25,000;
- Audit committee chairperson: $20,000;
- Compensation committee chairperson: $13,000; and
- Nominating/corporate governance committee chairperson: $10,000.

The Chairperson of our science and technology advisory committee, Dr. Ringrose, also received a fixed annual retainer of $10,000.

The members of our board of directors are eligible of reimbursement for their expenses incurred in attending board meetings in accordance with our policies.
Each of our non-employee directors is also compensated with periodic automatic grants of equity awards under a program implemented under our 2013 Equity Incentive Plan. These grants are non-discretionary, and only our non-employee directors are eligible to receive these automatic grants.

Under our automatic grant program, each individual who first becomes a non-employee director will, on the date such individual joins our board of directors, automatically be granted a one-time nonstatutory share option grant covering 12,000 ordinary shares. These initial option grants vest monthly over the director's first two years of service. In addition, on the date of joining our board of directors, a new non-employee director will also receive the standard annual equity awards (if joining on the date of our annual general meeting) or pro-rated annual equity awards (if joining on any other date), as described below. The pro-ration will be based upon the number of months of service the new board member will provide during the 12-month period ending on the one-year anniversary of the most recent annual general meeting.

Annually (if applicable, upon his or her re-election to our board of directors at the annual general meeting), each non-employee director is automatically granted the following equity awards: (i) a grant of restricted share units ("RSUs") covering ordinary shares with a grant date value of $200,000 and (ii) a nonstatutory share option grant covering 6,000 ordinary shares. These RSUs vest in full on the earlier of the one-year anniversary of the date of grant or the next annual general meeting, subject to continued service through such date. The share options vest monthly over one year of service.

All automatic equity awards vest in full if we are subject to a change in control or the board member dies or becomes disabled while in service. Each share option granted pursuant to the automatic grant program will have an exercise price equal to the fair market value of our ordinary shares on the date of grant, a term of up to ten years and will remain exercisable for three years following termination of a director's service other than for cause. Each RSU granted pursuant to the automatic grant program will be settled by issuing our ordinary shares upon vesting and includes cash dividend equivalent rights in the event we pay any cash dividends to shareholders while the award is outstanding.

In addition to the automatic equity awards described above, directors are also eligible to receive other equity awards under our 2013 Equity Incentive Plan.
## 2019 Director Compensation Table

The following table sets forth the compensation awarded to, earned by, or paid to each person who served as a director during 2019, other than a director who also served as a named executive officer.

<table>
<thead>
<tr>
<th>Name</th>
<th>Fees Earned or Paid in Cash ($)(1)</th>
<th>Share Awards ($)(2)(3)</th>
<th>Option Awards ($)(2)(4)</th>
<th>Total ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eran Broshy</td>
<td>84,500</td>
<td>199,982</td>
<td>68,897</td>
<td>353,379</td>
</tr>
<tr>
<td>Robert V. Gunderson, Jr.</td>
<td>69,000</td>
<td>199,982</td>
<td>68,897</td>
<td>337,879</td>
</tr>
<tr>
<td>Burton G. Malkiel, Ph.D.</td>
<td>113,000</td>
<td>199,982</td>
<td>68,897</td>
<td>381,879</td>
</tr>
<tr>
<td>Dean J. Mitchell</td>
<td>91,000</td>
<td>199,982</td>
<td>68,897</td>
<td>359,879</td>
</tr>
<tr>
<td>Susan Molineaux, Ph.D.</td>
<td>87,000</td>
<td>199,982</td>
<td>68,897</td>
<td>355,879</td>
</tr>
<tr>
<td>Donal O'Connor</td>
<td>91,000</td>
<td>199,982</td>
<td>68,897</td>
<td>359,879</td>
</tr>
<tr>
<td>Peter S. Ringrose, Ph.D.</td>
<td>84,500</td>
<td>199,982</td>
<td>68,897</td>
<td>337,879</td>
</tr>
<tr>
<td>Laurie Smaldone Alsup, M.D.</td>
<td>71,000</td>
<td>199,982</td>
<td>68,897</td>
<td>339,879</td>
</tr>
<tr>
<td>George M. Whitesides, Ph.D.</td>
<td>69,000</td>
<td>199,982</td>
<td>68,897</td>
<td>337,879</td>
</tr>
<tr>
<td>William D. Young</td>
<td>125,000</td>
<td>199,982</td>
<td>68,897</td>
<td>393,879</td>
</tr>
</tbody>
</table>

(1) Includes the annual retainers paid to each director for service in 2019, as well as fees for attendance at board of director and committee meetings in 2019.

(2) The amounts in these columns represent the aggregate grant date fair value of share awards and option awards granted to the director during 2019 computed in accordance with FASB ASC Topic 718. See Notes 1 and 11 of the notes to our consolidated financial statements in our Annual Report on Form 10-K filed on February 27, 2020 for a discussion of all assumptions made by us in determining the grant date fair value of our equity awards.

(3) As of December 31, 2019, each of the above listed directors held outstanding, unvested RSUs under which 8,385 ordinary shares were issuable.

(4) As of December 31, 2019, the above-listed directors held outstanding options to purchase the following number of our ordinary shares: Mr. Broshy (36,000); Mr. Gunderson (36,000); Dr. Malkiel (36,000); Mr. Mitchell (36,000); Dr. Molineaux (24,000); Mr. O'Connor (24,000); Dr. Ringrose (36,000); Dr. Smaldone Alsup (25,500); Dr. Whitesides (36,000); and Mr. Young (36,000). As of December 31, 2019, certain of the above-listed directors also held outstanding options to purchase the following number of shares of Innoviva, Inc.'s ("Innoviva") common stock: Mr. Gunderson (22,755); Dr. Malkiel (30,340); Dr. Ringrose (22,755); Dr. Whitesides (30,340); and Mr. Young (22,755). The Innoviva options held by our non-employee directors are fully vested, but, in connection with our spin-off from Innoviva in 2014, they were amended to remain outstanding based on service on our board of directors.

### Non-Employee Director Share Ownership Guidelines

Effective January 1, 2018, our board of directors adopted share ownership guidelines for our non-employee directors. Pursuant to these guidelines, beginning on the later of January 1, 2023 or after five years of service, non-employee directors are expected to hold shares (including RSUs, and whether or not vested) with a value equal to at least five times their annual base cash retainer.

### Hedging Policy Disclosure

Pursuant to our insider trading policy, all our directors, officers, employees and agents (such as consultants and independent contractors) as well as the members of their immediate family, persons with whom they share a household, persons that are their economic dependents and any other individuals or entities whose transactions in securities they influence, direct or control are prohibited.
from engaging in transactions in publicly traded options on our securities, such as puts, calls and other derivative securities, on an exchange or in any other organized market. Although our Insider Trading Policy requires that all such individuals receive permission from one of our senior legal officers before entering into any hedging or monetization transactions, we have not and do not intend to in the future approve any such transactions. The full text of our insider trading policy is posted on the Investor Relations portion of our website at www.theravance.com.

Shareholder Communications with the Board of Directors

Shareholders interested in communicating with the board of directors or a particular director should send correspondence to Theravance Biopharma, Inc., c/o of its U.S. subsidiary, Theravance Biopharma US, Inc., at 901 Gateway Boulevard, South San Francisco, California 94080, Attn: Secretary. Each communication should set forth (i) the name and address of the shareholder as it appears on our books and, if the shares are held by a nominee, the name and address of the beneficial owner of the shares, and (ii) the number of ordinary shares that are owned of record by the record holder and beneficially by the beneficial owner. Pursuant to our Shareholder—Director Communications Policy & Procedures, the Secretary has been instructed, in his discretion, to screen out communications from shareholders that are not related to the duties and responsibilities of the board of directors. If deemed an appropriate communication, the Secretary will forward it, depending on the subject matter, to the chairperson of a committee of the board of directors or a particular director, as appropriate.
The following table provides information concerning our executive officers as of March 2, 2020:

<table>
<thead>
<tr>
<th>Name</th>
<th>Age</th>
<th>Position(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick E Winningham</td>
<td>60</td>
<td>Chief Executive Officer and Chairman of the Board</td>
</tr>
<tr>
<td>Ann B. Brady</td>
<td>53</td>
<td>President, Theravance Biopharma Ireland Limited</td>
</tr>
<tr>
<td>Brett K. Haumann</td>
<td>50</td>
<td>Senior Vice President, Clinical Development and Chief Medical Officer</td>
</tr>
<tr>
<td>Andrew A. Hindman</td>
<td>47</td>
<td>Senior Vice President and Chief Financial Officer</td>
</tr>
<tr>
<td>Frank Pasqualone</td>
<td>64</td>
<td>Senior Vice President and Chief Commercial Operations</td>
</tr>
<tr>
<td>Kenneth R. Pitzer</td>
<td>56</td>
<td>Senior Vice President, Product Strategy and Commercial Planning</td>
</tr>
<tr>
<td>Vijay Sabesan</td>
<td>47</td>
<td>Senior Vice President, Technical Operations</td>
</tr>
<tr>
<td>Bradford J. Shafer</td>
<td>59</td>
<td>Executive Vice President, General Counsel and Secretary</td>
</tr>
<tr>
<td>Philip D. Worboys</td>
<td>50</td>
<td>Senior Vice President, Research and Translational Science</td>
</tr>
</tbody>
</table>

*Rick E Winningham.* See biographical information set forth above under “Proposal One: Election of Directors—Information Regarding the Nominees and Other Directors.”

*Ann B. Brady, Ph.D.* joined Theravance Biopharma in April 2016 as President, Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc., where she is responsible for the leadership and growth of the Company’s operation based in Dublin, Ireland. In addition, Dr. Brady leads the company’s Global Alliance Management activities with responsibility for Theravance Biopharma’s portfolio of strategic partnerships. Prior to joining Theravance Biopharma, Dr. Brady served as Vice President, Alliance Management & New Market Development at Shire, plc where from 2007-2014 she led the expansion of Shire’s business in Europe, Asia and Latin America via the establishment of local operating companies and the formation of strategic alliances. She also served as Executive Director on the Board of Shire Pharmaceuticals Ireland, Ltd. from December 2007 until March 2014. Dr. Brady began her career at Elan Corporation, plc and served in broad ranging roles of increasing responsibility across R&D, Operations, Commercial Management and Corporate Development, including Vice President, Business Development, during her 15 year tenure. She also serves as a Non-Executive Director on the Board of an early stage, privately held biopharmaceutical company, Avectas Ltd. Dr. Brady holds a BA (Mod) and PhD in Chemistry from Trinity College, Dublin and is a Chartered Director (C Dir) of The Institute of Directors.

*Brett K. Haumann, M.D.* joined Theravance Biopharma in June 2014 in connection with our spin-off from Innoviva, after joining Innoviva as Vice President, Clinical Development, in October 2013. He became Vice President, Clinical Development and Operations of Innoviva in March 2014 and became Senior Vice President, Clinical Development at Theravance Biopharma in December 2014. Dr. Haumann served as Chief Medical Officer at, and on the board of directors of Circassia Limited, a biopharmaceutical company from September 2012 to June 2013 and on the board of directors of Reacta Biotech LTD from June 2014 to November 2016. Dr. Haumann held senior positions at GlaxoSmithKline, including Medicines Development Leader and Vice President Clinical Development until August 2012. Dr. Haumann has more than 20 years of experience in the discovery and development of pulmonary and allergy medicines. He is a member of the board of directors of Aimmune Therapeutics, Inc. Dr. Haumann completed his M.D. at the University of Witwatersrand Medical School, South Africa and holds an M.B.A. from Open University, United Kingdom.

*Andrew A. Hindman* joined Theravance Biopharma in June 2019 as Senior Vice President and Chief Financial Officer. Prior to Theravance Biopharma, Mr. Hindman held several senior executive level positions in the biopharmaceutical industry, most recently as Chief Business Officer of Acorda Therapeutics since March 2018 and prior to that role he served as their Chief Business Development Officer from May 2014 to March 2018. Before joining Acorda, from April 2011 to January 2014, Mr. Hindman served as President, Chief Executive Officer and member of the board of Tobira.
Therapeutics, a privately-held biotechnology company that was acquired by Allergan in 2016. Prior thereto, Mr. Hindman held senior corporate development and commercial operating positions, including from 2010 to 2011 at Nodality, Inc., from 2008 to 2010 at Onyx Pharmaceuticals, Inc., and from 1998 to 2008 at Gilead Sciences, Inc. Prior to his operating roles, Mr. Hindman was a member of the Healthcare Investment Banking Group at J.P. Morgan. Mr. Hindman holds a B.A. in Economics and MB&B (molecular biology and biochemistry) from Wesleyan University where he graduated Phi Beta Kappa with High Honors (Economics), and an executive M.B.A. from Columbia University and the University of California, Berkeley, Haas School of Business.

**Frank Pasqualone** joined Theravance Biopharma as Senior Vice President, Operations in June 2014 in connection with our spin-off from Innoviva. Prior to the spin-off, Mr. Pasqualone held the position of Senior Vice President, Operations at Innoviva since January 2014. From 2010 to 2012, he served as President of Intercontinental Region: Latin America, Middle East and Africa and also as President of Southern Europe from 2009 to 2010, at Bristol-Myers Squibb (BMS). Over a 25-year period with BMS, Mr. Pasqualone held senior management positions in the U.S. and globally. In the U.S., he was responsible for the Oncology/Virology business and led the marketing group in the Diabetes business. Since leaving Bristol-Myers Squibb and prior to joining Theravance, Mr. Pasqualone was self-employed as a part-time consultant. Mr. Pasqualone holds an M.B.A. from University of Dayton and a B.S. in Marketing from Bowling Green State University in Ohio.

**Kenneth R. Pitzer, D.V.M.**, has served as our Senior Vice President, Product Strategy and Commercial Planning since March 2016. Previously, Dr. Pitzer was Vice President, Strategic and Commercial Planning since he joined Theravance Biopharma in October 2014 from Innoviva, where he held the position of Vice President, Strategic and Commercial Planning since January 2008. Dr. Pitzer joined Innoviva in 2002 as Director, New Product Planning, and held various positions in the Commercial Development Department before being promoted to Vice President, Strategic and Commercial Planning in January 2008. Prior to joining Innoviva Dr. Pitzer worked at Lederle Laboratories, a pharmaceutical manufacturing company, as Marketing Manager from 1989 to 1995 and then at Cygnus, Inc., a biopharmaceutical company, from 1995 until 2002, ultimately serving as the Vice President of Product Management. Dr. Pitzer earned a Doctor of Veterinary Medicine degree from The Ohio State University in 1987 and an M.B.A. from Carnegie-Mellon University in 1989.

**Vijay Sabesan** has served as our Senior Vice President of Technical Operations since February 2019, prior to which he served as Vice President of Technical Operations since February 2017 and Vice President of Process R&D since February 2016. He joined the company in June 2014 in from Innoviva as Senior Director of Process R&D. With Innoviva from 2004 to June 2014, he held various positions, ultimately serving as the Senior Director of Process R&D. Prior to joining Innoviva, Mr. Sabesan worked in the chemical process development group at Schering-Plough Research Institute from 1997 to 2004. Mr. Sabesan has a B.Tech. in Chemical Engineering from the Indian Institute of Technology, Madras, and an M.S. in Chemical Engineering from Rutgers University.

**Bradford J. Shafer** has served as our Executive Vice President, General Counsel since March 2016 and our Secretary since November 2014. Previously, he was our Senior Vice President, General Counsel since September 2014. Prior to joining Theravance Biopharma, Mr. Shafer served as Senior Vice President, General Counsel and Secretary at Innoviva, since August 1999. From 1996 to 1999 he served as General Counsel of Heartport, Inc., a medical device company. From 1993 to 1996, Mr. Shafer was a partner in the Business and Technology Group at the law firm of Brobeck, Phleger & Harrison LLP. Mr. Shafer holds a J.D. from the University of California, Hastings College of the Law, where he was Editor-in-Chief of The Hastings Constitutional Law Quarterly, and a B.A. from the University of the Pacific, where he graduated magna cum laude.

**Philip D. Worboys, Ph.D.**, has served as our Senior Vice President, Translational Science since March 2016, where is he responsible for leading the progression of drug candidates from the discovery
stage into human clinical studies, including clinical pharmacology and biomarker development as well as project management. Previously, Dr. Worboys was Vice President, Drug Metabolism and Pharmacokinetics (DMPK) since he joined Theravance Biopharma in October 2014 from Innoviva, where he held the position of Vice President, DMPK since November 2008. Prior to joining Innoviva, he served as Senior Director, DMPK at Roche Bioscience, Inc. since 2005. Dr. Worboys was an Associate Director, DMPK at Pharmacia Corporation from 2001 until its acquisition by Pfizer, Inc. and was Senior Director, DMPK at Pfizer, Inc. from 2003 to 2005. He spent the first part of his career in DMPK, at Merck Sharp & Dohme in Harlow, United Kingdom, and worked in various capacities at Aventis, Unilever and GlaxoSmithKline prior to that. Dr. Worboys obtained his Ph.D. degree in Pharmaceutics from Manchester University, United Kingdom. He holds a B.Sc. degree in Biochemistry from Imperial College of Science, Technology & Medicine at the University of London.
EXECUTIVE COMPENSATION

Compensation Discussion and Analysis

This section discusses our executive compensation policies and decisions and the most important factors relevant to an analysis of these policies and decisions. It provides qualitative information regarding the manner and context in which compensation is awarded to and earned by our named executive officers and offers perspective on the data presented in the tables and narrative that follow.

Executive Summary

We are a biopharmaceutical company that operates in an extremely competitive, rapidly changing and heavily regulated industry. We believe that the skill, talent, judgment and dedication of the executive officers and other employees are critical factors affecting our long-term shareholder value. Therefore, our goal is to maintain a compensation program that will fairly compensate employees while attracting and retaining highly qualified employees, motivating their performance and rewarding the achievement of key corporate goals. We also aim to align employees' long-term interests with those of our shareholders.

Our portfolio spans a number of therapeutic areas and includes products in every stage of development from investigation and discovery, through early-, mid- and late-stage clinical trials, to a marketed commercial product. It is important that our named executive officers understand the tactical and strategic elements of every program in our portfolio while the program progresses from research to development to commercialization and life cycle management. The breadth and depth of our portfolio requires current knowledge of, and facility with, complex issues encompassing patient needs, prescriber concerns and priorities, institutional dynamics, the insurance reimbursement landscape for patients, as well as the priorities, plans, strengths and weaknesses of our competitors and potential partners. Our named executive officers must work in an integrated manner to maximize the value of each program, whether the program is wholly owned by Theravance Biopharma or rights and responsibilities are shared with a partner, and to enable our research organization to discover and develop impactful new therapies.

2019 Corporate Highlights

Highlights of our performance in 2019 included the following:

- Our annualized total shareholder return (TSR) for the five-year period ending December 31, 2019 was a compound growth rate of 12%, which is at approximately the 68th percentile relative to our 2019 peer group described below.

- Early performance indicators suggest that YUPELRI® (revefenacin) inhalation solution for the maintenance treatment of patients with COPD is realizing strong customer acceptance and market uptake.

- We completed two corporate development transactions that (i) licensed development and commercialization rights to nebulized revefenacin in China and adjacent territories to Mylan and (ii) licensed rights to our preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitors that can be rapidly metabolized to Pfizer.

Compensation Philosophy and Objectives

The difficulty of achieving our goals in the time frames specified, as well as the high level of drug development and leadership experience of the officer team, motivates our compensation philosophy and the emphasis on longer-term compensation.
In order to attract, retain and incentivize our named executive officers, our compensation philosophy is to provide a competitive pay package with significant upside potential. In addition, we emphasize long-term equity compensation over annual cash compensation to align our compensation with the long-term nature of the drug development and commercialization cycle. We also strive to design officer compensation to reward annual goal achievement and increased shareholder value, while keeping focus on and providing potential reward for achievement of multi-year goals that we believe will create significant value for our shareholders over time. We believe that successful execution against the goals we set is the best way to enhance enduring shareholder value. Accordingly, our annual cash incentives and a portion of our longer term incentives granted to named executive officers are tied to achievement of corporate operating, drug development and commercialization goals.

Our aggressive annual and longer-term operating goals generally relate to the successful discovery, development, regulatory approval and commercialization of our compounds, as well as the identification and execution of strong strategic partnerships. The business of discovering novel compounds and developing them as potential medicines is risky, the current regulatory environment for new drug approvals is uncertain and the field is highly competitive. Once a compound is approved for sale, then successful commercialization is challenging, with not only physicians and patients but also third party payors influencing success. In addition, we set operating goals that must be achieved in a relatively short time-frame to earn incentives. We typically set more goals than we reasonably believe we can accomplish in a given time frame in order to drive the leadership team's performance and set a tone of high achievement.

Corporate Governance Policies

Our executive officers are subject to share ownership guidelines. The share ownership guidelines require each of our executive officers to own shares equal in value to a multiple of six times the base salary for the CEO and two times the base salary for our other executive officers. Ownership requirements may be met by shares and restricted share units, whether or not vested, and exclude shares still subject to a performance requirement. Executive officers are required to be in compliance with these guidelines by January 1, 2023, or, if later, by the five-year anniversary of their becoming an executive officer. Thereafter, compliance will be measured annually. If, at the compliance measurement date, the executive officer does not meet the guideline, then until such officer is in compliance, he or she will be expected to hold 50% of our after-tax shares acquired thereafter, whether by option exercise, vesting or settlement of equity awards.

Compensation Committee

The compensation committee of our board of directors is comprised of four non-employee members of the board of directors. The compensation committee's basic responsibility is to review the performance of our management relative to achievement of corporate objectives and to ensure that the named executive officers and other members of senior management are compensated in a manner consistent with competitive practice. In fulfilling this responsibility, the compensation committee reviews the performance of each named executive officer at least once each year, and generally twice per year. The CEO, as the manager of the executive team, assesses the executives' contributions to the corporate goals and makes a recommendation to the compensation committee with respect to any merit increase in salary, cash bonus and annual replenishment equity award for each member of the executive team, other than himself. The compensation committee meets with the CEO to evaluate, discuss and modify or approve these recommendations. The compensation committee also conducts a similar evaluation of the CEO's contributions when the CEO is not present, and determines any increase in salary, cash bonus and annual replenishment equity award for him.

The compensation committee reviews the named executive officers' compensation when we provide the compensation committee with compensation summaries for each executive officer at the beginning.
of each year. The information in these summaries is used by the compensation committee to assist with analyzing existing compensation and any proposed changes in compensation for each named executive officer. The summaries include market data, information regarding the accumulated value of unvested equity ownership, how much is unvested, and the amount of potential value earnable under various share price scenarios.

The summaries help the compensation committee to track changes in an officer's total direct compensation from year to year and to remain aware of the compensation historically paid to each named executive officer. In addition to the information and analyses supplied to the compensation committee as described above and in the peer group segment below, members of management support the compensation committee in its work from time to time and the compensation committee's independent executive compensation consultant provides compensation analyses, in each case, at the compensation committee's request.

Advisory Vote on Executive Compensation

Our most recent advisory vote on named executive officer compensation took place at our 2017 annual meeting of shareholders, where over 97% of our shareholders voted "For" a non-binding advisory resolution approving the compensation of our named executive officers, as disclosed in the proxy statement for that meeting. Our compensation committee reviewed the results of the 2017 advisory vote and viewed the high level of shareholder support as an affirmation of our compensation policies. As a result, our compensation committee concluded that no revisions were necessary to our named executive officer compensation program or philosophy.

At our 2017 annual meeting of shareholders, our shareholders also approved holding a vote on executive compensation every three years. As a result, at this year's annual meeting our shareholders are again being asked to cast a non-binding advisory vote in favor of the compensation of our named executive officers described herein.

Compensation Consultant

The compensation committee has the authority under its charter to engage the services of outside advisors, experts and others to assist the compensation committee. In accordance with this authority and as described in the "Corporate Governance—Board Committees—Compensation Committee" section beginning on page 22, the compensation committee confers from time to time with its independent executive compensation consultant, Frederic W. Cook & Co. ("FW Cook"). FW Cook is retained by and reports directly to the compensation committee and its role is to assist and advise the compensation committee on matters related to compensation for executive officers, other key employees and non-employee directors. FW Cook does not work on projects for management except as an agent of the compensation committee and with the advance knowledge and approval of the chairman of the compensation committee. The compensation committee has the sole authority to retain and dismiss its outside compensation consultants.

Peer Group

The peer group used to evaluate 2019 compensation decisions was established in September 2017 (the "2017 Peer Group"), taking into account the advice of FW Cook. The peer selection process focused on companies with average 2016 market capitalization between 0.25x and 5.0x of our market capitalization at the time the peers were chosen. The goal was to generally position our market capitalization near the median of the peer group. At the time our peers were selected in late 2017, our market capitalization was $1.6 billion, which was higher than the new peer group median of $1.3 billion on average in 2016. In selecting peer companies, 2016 average market capitalization was considered the primary size criterion because market capitalization is directly correlated to share price, which can drive
equity compensation use and reported executive officer grant values. The 2017 Peer Group consists of the following twenty-three companies:

| 2017 Peer Group |
|-----------------|-----------------|
| Acorda Therapeutics | Intersect ENT |
| Agios Pharmaceuticals | Ionis Pharmaceuticals |
| Alnylam Pharmaceuticals | Ironwood Pharmaceuticals |
| Assertio (formerly known as Depomed) | Juno Therapeutics* |
| Bluebird Bio | Nektar Therapeutics |
| Clovis Oncology | Neurocrine Biosciences |
| Dynavax Technologies | Portola Pharmaceuticals |
| Exelixis | PTC Therapeutics |
| FibroGen | Retrophin |
| Five Prime Therapeutics | Seattle Genetics |
| Halozyme Therapeutics | Ultragenyx Pharmaceutical |
| Heron Therapeutics | |

* Acquired in 2018.

The compensation committee typically revisits the peer group every two years. In August 2019, FW Cook revised the peer group (the “2019 Peer Group”) to align with our smaller market capitalization, and which was then used to evaluate 2020 compensation decisions. The 2019 Peer Group criteria focused on companies with market capitalization between 0.4x and 4x our market capitalization, which resulted in a targeted range of $0.5 billion to $4.8 billion in light of our $1.2 billion market capitalization at the time. An additional peer company, Bluebird Bio, was also included despite its larger market capitalization of $8.4 billion, because we view it as a comparable company to ours and a direct competitor for talent. The 2019 Peer Group consisted of the following twenty-one companies:

| 2019 Peer Group |
|-----------------|-----------------|
| Agios Pharmaceuticals | Heron Therapeutics |
| Amarin | ImmunoGen |
| Arena Pharmaceuticals | Ironwood Pharmaceuticals |
| Bluebird Bio | Portola Pharmaceuticals |
| Corcept Therapeutics | Prothena |
| CytoX Therapeutics | PTC Therapeutics |
| Eagle Pharmaceuticals | Radius Health |
| FibroGen | Retrophin |
| Five Prime Therapeutics | Ultragenyx Pharmaceutical |
| Global Blood Therapeutics | Zogenix |
| Halozyme Therapeutics | |

We operate in an intensely competitive labor market in which talented employees typically have many alternatives and it is relatively easy to change jobs. Accordingly, our CEO and compensation committee review data about the compensation of similar officers at the peer group companies when making decisions. The company's view is that compensation should generally be at least at the median of the peer data, which are used as a reference point without targeting a particular benchmark. Compensation decisions are informed by factors specific to our company and the individual named executive officers. For example, we believe that our portfolio of research and development programs, which currently includes multiple compounds in clinical development for the treatment of multiple disease states, and our marketing, with our partner Mylan, of an approved product, is generally broader than those of companies in our peer group, which affects the skills and experiences needed by our officers and in turn affects our compensation decisions to attract and retain them.
Principal Elements of Compensation

Base Salaries

Base salaries are set to reflect compensation commensurate with the individual's current position, work experience and contribution. Our goal in this regard is to attract and retain high caliber talent for the position and to provide a base wage that is not subject to performance risk. Salary for the CEO and the other named executive officers is determined based on the underlying scope of their respective responsibilities, their personal experience working at innovative drug discovery companies, and takes into account competitive market compensation data as a reference point. We review base salaries for the named executive officers annually, generally in the first quarter of each year. The CEO proposes salary adjustments to the compensation committee (other than for himself) based on any changes in competitive market salaries, individual performance and/or changes in job duties and responsibilities. The compensation committee then determines any salary adjustment applicable to each of the named executive officers.

In February 2019, our compensation committee approved the following base salary increases for our named executive officers other than Mr. Hindman, whose base salary was negotiated at the time of hire in 2019:

<table>
<thead>
<tr>
<th>Name</th>
<th>Increase in Annual Base Salary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick E Winningham</td>
<td>3%</td>
</tr>
<tr>
<td>Brett K. Haumann</td>
<td>3.75%</td>
</tr>
<tr>
<td>Frank Pasqualone</td>
<td>3%</td>
</tr>
<tr>
<td>Bradford J. Shafer</td>
<td>3.75%</td>
</tr>
</tbody>
</table>

The reference amount the compensation committee allocated for employee merit increases was generally 3.5%. Messrs. Pasqualone, Shafer and Winningham and Dr. Haumann each received an increase that was based on the compensation committee's assessment of their performance and individual contributions to the 2019 goals, taking into account peer group compensation data.

Annual Cash Incentive Compensation

Our named executive officers are eligible for annual cash incentives under our company-wide bonus program which is designed to reward the achievement of key corporate goals established by our board of directors at the beginning of the year and which we believe should increase shareholder value over time as well as individual performance.

Each named executive officer has a target bonus stated as a percentage of annual base salary for the year. For 2019, target bonus percentages were 50% of annual base salary for the year for executive and senior vice presidents and 60% of annual base salary for the year for our CEO, which reflects no changes from 2018 target bonus percentages.

The corporate goals applicable to the annual bonus program are established by our full board of directors at the beginning of the year as part of our annual business plan and communicated to employees. For 2019, the goals were grouped into five distinct categories, which were weighted based on the compensation committee's assessment of their relative importance to the creation of long-term shareholder value. Each category is eligible for a score of up to 150% of the assigned weighting, at the discretion of our compensation committee. The individual goals within each category are not weighted in order to provide the compensation committee with the flexibility to determine the importance of individual goals based on a variety of factors, which include actual results, changing business conditions throughout the year and operating challenges that were not reasonably foreseeable at the time the goals were established.
At the end of the year, our compensation committee reviewed performance against the corporate goals and determined the overall score for each category, which determined the size of the bonus pool for all employees. In making these determinations and assessing individual performance, the compensation committee considers information presented by our CEO and Senior Vice President, Human Resources, Organization and Leadership on our company-wide performance against goals and the individual contributions of the named executive officers toward achievement of the goals. The corporate score is the sum of the scores in each category and for 2019 resulted in funding of the bonus pool at 85% of target. However, at the recommendation of management, the compensation committee determined the cash bonus pool would be set at 80% of target for the company’s executives as those ultimately responsible for the Company's performance of its goals.

After determining the size of the company-wide bonus pool, a named executive officer's individual bonus may be increased or decreased by 50% based on a subjective assessment of individual performance, up to a maximum bonus of 150% of target. While individual bonuses may be adjusted based on performance, the overall size of the bonus pool may not exceed the amount funded based on the corporate performance score.

The table below lists the goals, grouped by category, that applied to our 2019 cash bonus program, including our compensation committee's determination of the achievement score (out of 150%) awarded for each category.

<table>
<thead>
<tr>
<th>Category</th>
<th>2019 Corporate Goals</th>
<th>Weighting</th>
<th>Achievement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial</td>
<td>• YUPELRI (Reverfenacin) Inhalation Solution: Achieve Net Sales of $48.9M</td>
<td>30%</td>
<td>133%</td>
</tr>
<tr>
<td>Development</td>
<td>• Complete enrollment in Peak Inspiratory Flow Rate (PIFR) studies of YUPELRI</td>
<td>35%</td>
<td>14%</td>
</tr>
<tr>
<td></td>
<td>• Pivotal Phase 3 Studies of Ampreloxetine (TD-9855)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Clinical Studies of TD-1473</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Translational Science</td>
<td>• Complete enrollment in Phase 2 lung allergen challenge of TD-8236 in asthma</td>
<td>15%</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td>• Report positive results from Phase 1 single ascending dose (SAD)/multiple ascending dose (MAD) study of TD-5202 in healthy volunteers</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Complete investigational new drug (IND) enabling packages for at least one program</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research</td>
<td>• Nominate development candidates for at least two programs</td>
<td>10%</td>
<td>100%</td>
</tr>
<tr>
<td>Corporate</td>
<td>• Achieve year-end cash balance of ~2 years projected burn</td>
<td>10%</td>
<td>150%</td>
</tr>
<tr>
<td></td>
<td>• Complete Corporate/Business Development transaction(s), based on business needs</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Report metrics to confirm that we are attracting, retaining, and developing an engaged and passionate workforce</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total:</strong></td>
<td></td>
<td>100%</td>
<td>85%</td>
</tr>
</tbody>
</table>
In determining the size of our 2019 bonus pool, the compensation committee made the following determinations:

- **Commercial.** We exceeded an aggressive net sales goal for 2019 with early performance indicators suggesting that YUPELRI® (revefenacin) inhalation solution for the maintenance treatment of patients with COPD is realizing strong customer acceptance and market uptake. Additionally, market research indicated a high percentage of patients who were prescribed YUPELRI while in the hospital were discharged with a prescription for use as an outpatient.

- **Development.** We did not meet our 2019 development goals. However, in recognition of (1) progress made in the advancement of each of the clinical programs; and (2) agreement with our partner to execute a clinical program in COPD patients with low peak inspiratory flow, the compensation committee awarded a small partial achievement in this category.

- **Translational Science.** We achieved the goals within this category. Importantly, we demonstrated proof of principle in a TD-8236 Phase 1 study with improvement of exhaled nitric oxide in asthma patients and made significant progress in the enrollment in the TD-8236 Phase 2 study.

- **Research.** We nominated one development candidate in 2019, and the work required to nominate a second development candidate was completed in December 2019. When considering the reduction in force which took place in the first quarter of 2019, the achievement of the research and translational science goals was quite significant. Accordingly, our compensation committee considered this goal achieved.

- **Corporate.** Our compensation committee determined we exceeded the goals set in this category. Most notably, the company executed two business development transactions—the expansion of our development and commercialization agreement with Mylan for nebulized revefenacin to include China and certain adjacent territories and our global license agreement with Pfizer for our preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitors—both of which our compensation committee considered reflected well on our research capabilities, provided unbudgeted revenues in 2019 and has the potential to later result in significant milestones and royalties. Additionally, our cash, cash equivalents and marketable securities totaled $285.8 million as of December 31, 2019. Additionally, we measure alignment of our employees with the strategic objectives of the company through a company-wide survey, which indicated a relatively high level of alignment between our team and our strategic objectives.

In the case of our executive officers, our compensation committee set the bonus pool at 80%, as opposed to 85% for other employees, as a result of the failure to more fully execute on our 2019 goals. Our compensation committee exercised discretion to decrease Dr. Haumann's bonus amount to 62% due to insufficient advancement of our clinical programs in 2019. Our compensation committee exercised its discretion to increase Mr. Pasqualone's bonus to 86% in recognition of his significant leadership role in YUPELRI's launch.

The actual bonuses awarded to our named executive officers other than Ms. Gala (who resigned at the beginning of 2019 and was not eligible to receive a bonus), are shown in the table below and
reflected in the Bonus and Non-Equity Incentive Compensation columns of the "Summary Compensation Table" on page 44:

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Cash Bonus ($)</th>
<th>Percentage of Target (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick E Winningham</td>
<td>Chief Executive Officer</td>
<td>473,906</td>
<td>80</td>
</tr>
<tr>
<td>Andrew A. Hindman</td>
<td>Senior Vice President and Chief Financial Officer</td>
<td>216,000</td>
<td>80</td>
</tr>
<tr>
<td>Brett K. Haumann</td>
<td>Senior Vice President, Clinical Development and Chief Medical Officer</td>
<td>170,000</td>
<td>62</td>
</tr>
<tr>
<td>Frank Pasqualone</td>
<td>Senior Vice President and Chief Commercial Operations Officer</td>
<td>225,000</td>
<td>86</td>
</tr>
<tr>
<td>Bradford J. Shafer</td>
<td>Executive Vice President, General Counsel and Secretary</td>
<td>215,611</td>
<td>80</td>
</tr>
</tbody>
</table>

**Equity Incentive Compensation**

We believe that successful research, development and commercialization of medicines requires excellent functional expertise. However, functional expertise alone will not result in approved medicines, successful customer interactions or a successful company. Our long-term equity incentives seek to support our strategy of attracting employees with excellence and expertise in functional areas (e.g. medicinal chemistry, different disciplines of biology, physical chemistry, process chemistry, clinical science, clinical trial execution, partnering and collaboration, strategic marketing, marketing science and financial planning). Equally as important, our equity incentive plans seek to support an environment of extraordinary teamwork as well as long-term retention of our employees in an intensely competitive environment.

The types of equity compensation comprising the mix of officer compensation consist of: (i) options with time-based vesting, which require the market value of our ordinary shares to increase before they are valuable; (ii) performance-contingent restricted share awards ("RSAs") or restricted share unit awards ("RSUs"), the right to which is dependent upon successful completion of corporate performance goals; and (iii) RSUs with time-based vesting. We do not use a targeted cash/equity split to set officer compensation. In 2019, we granted RSUs with time-based vesting to all of our named executive officers other than Ms. Gala, who resigned at the beginning of 2019, and in connection with the commencement of his employment with us, we also granted options with time-based vesting and RSUs with performance-based vesting to Mr. Hindman.

Generally, in order to align the officer's interests with those of our shareholders, a significant option grant is made to a named executive officer at the first regularly scheduled meeting of the compensation committee after the officer commences employment. Annual replenishment equity awards generally are considered during the first quarter of each year, and additional equity awards may be made in connection with an officer earning a promotion or taking on additional duties or for retention purposes in certain circumstances. Options have been used primarily as a hiring incentive, with annual replenishment awards provided in the form of RSUs. Replenishment equity awards are granted annually and generally vest over a four-year period. We believe that the resulting overlapping vesting schedule from awards made in prior years, together with the number of shares subject to each award, helps ensure a meaningful incentive to remain in our employ and to enhance shareholder value over time. Annual replenishment equity award grants to all employees generally are made during the first quarter of each year at a meeting of the compensation committee following annual employee performance reviews. In determining the size of equity awards granted to our named executive officers, our compensation committee considers such matters as it deems appropriate in its discretion, including individual and company performance and recommendations from our CEO. The compensation committee also references guidelines that provide the compensation committee with information about
the size of equity awards, both as a percentage of the company and based on grant value, at our peer companies.

In 2016, the compensation committee adopted the special Long-Term Retention and Performance Incentive Program, which is described in detail in our 2017 proxy statement and consisted of (1) 2016 replenishment RSUs twice the size of the guideline replenishment award for the executive officers, with extended five-year vesting and substantially reduced replenishment awards in each of 2017 and 2018; and (2) long term RSAs (or, in the case of Dr. Haumann, as a result of tax-related concerns in his country of residence at the time of grant, RSUs) offering the named executive officers the opportunity to earn higher value over the 2016-2020 timeframe depending on how many key operating goals and objectives are achieved during that five year period (the “Five-Year Performance RSAs”). The Five-Year Performance RSAs vest based on the achievement of critical operating goals and objectives over the 2016-2020 timeframe and continued employment. While the Long-Term Retention and Performance Incentive Program did not impact the annual replenishment awards that were granted to our named executive officers in 2019, the Five-Year Performance RSAs remain outstanding and are eligible to vest through 2020, as further discussed below. In addition, while Mr. Hindman was not employed by us when the Long-Term Retention and Performance Incentive Program was implemented and therefore is not a participant in that program, in connection with his hire in 2019 he was granted 60,000 performance-contingent RSUs with a goal of creating a similar performance incentive.

2019 Annual Replenishment RSUs

2019 replenishment equity awards granted to our named executive officers (other than Mr. Hindman) were set at a level that was around the 75th percentile as a percentage of the company in comparison to our peers.

The following table shows the number of replenishment RSUs that were granted to each of the named executive officers other than Mr. Hindman in the first quarter of 2019.

<table>
<thead>
<tr>
<th>Name and Title</th>
<th>2019 RSUs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick E Winningham</td>
<td>170,000</td>
</tr>
<tr>
<td>Chief Executive Officer</td>
<td></td>
</tr>
<tr>
<td>Brett K. Haumann</td>
<td>65,000</td>
</tr>
<tr>
<td>Senior Vice President, Clinical Development and Chief Medical Officer</td>
<td></td>
</tr>
<tr>
<td>Frank Pasqualone</td>
<td>65,000</td>
</tr>
<tr>
<td>Senior Vice President and Chief Commercial Operations Officer</td>
<td></td>
</tr>
<tr>
<td>Bradford J. Shafer</td>
<td>65,000</td>
</tr>
<tr>
<td>Executive Vice President, General Counsel and Secretary</td>
<td></td>
</tr>
</tbody>
</table>

Five-Year Performance RSAs

As described in detail in the “Equity Incentive Compensation” section of our 2017 proxy statement, the vesting of the Five-Year Performance RSAs granted to our named executive officers in 2016 hinges on the achievement of nine pre-specified milestones between 2016 and 2020, as well as continued employment. We believe the goals underlying the Five-Year Performance RSAs are strategically important for us and, if achieved in the manner set forth in the Long-Term Retention and Performance Incentive Program, should increase shareholder value substantially. There are three potential vesting events, upon the achievement of any combination of milestones that add up to at least 10, 15 and 20 achievement points. A complete list of the goals applicable to the Five-Year Performance RSAs is set forth in the “Equity Incentive Compensation” section of our 2017 proxy statement. Prior to 2019 three milestones—for Phase 3 Success, the first successful completion of a business development transaction and First Proof of Concept (LUNAR program) (meaning completion of a Phase 2a study that shows efficacy and tolerability of a compound in the Company's LUNAR program such that it...
would be reasonable to progress the compound to the next stage of development)—were achieved, which triggered the first vesting event for the Five-Year Performance RSAs and resulting in vesting of 25% of the shares subject to the awards.

In early 2019, the compensation committee certified the achievement of one additional milestone in 2018—NDA approval—which triggered the second vesting event for the Five-Year Performance RSAs and resulted in an additional 35% of the shares subject to the awards becoming eligible to vest on February 20, 2020 (subject to the officer’s continued employment through such date). In addition, in February 2020, the compensation committee certified achievement of an additional milestone for the second successful completion of a BD transaction based on the December 2019 execution of the License Agreement with Pfizer Inc., which triggered the third vesting event for the Five-Year Performance RSAs and resulted in the final 40% of the shares subject to the awards becoming eligible to vest on February 20, 2021 (subject to the officer’s continued employment through such date). When the Five-Year Performance RSAs were granted in 2016, we intended them to operate over a five-year period to incentivize and reward achievements that we believed would create long-term value for shareholders, provide for long-term retention, and align executives with long-term shareholders. Though the final goal was achieved in late 2019 and certified by the compensation committee in 2020, it will not vest or be paid to the officers participating in the Long-Term Retention and Performance Incentive Program until February 2021. Further, we believe that the achievement of performance milestones adding up to 20 points reflects superior performance given the challenge in completing these goals in the five-year timeframe and has resulted in significant value creation for our company.

2019 Equity Awards Granted to Mr. Hindman

In connection with Mr. Hindman’s commencement of employment with us, he was granted the following equity awards: (i) consistent with our general philosophy of granting options to new officers, an option for 260,000 ordinary shares, with vesting over a four-year period of employment following the commencement of his employment; (ii) RSUs for 50,000 ordinary shares, with vesting over four years (25% of the shares are scheduled to vest on August 20th of each of 2020, 2021, 2022 and 2023, subject to his continued employment); and (iii) in order to create a performance incentive similar to the Five-Year Performance RSAs granted to our other named executive officers as part of the Long-Term Retention and Incentive Program, performance-contingent RSUs for 60,000 ordinary shares. One-third of the performance-contingent RSUs vest upon certification of achievement of one of the performance milestones set forth below, an additional one-third of the performance contingent RSUs will vest on the one year anniversary following certification of achievement of a second performance milestone, and the remaining one-third of the performance-contingent RSUs will vest on the one year anniversary following certification of achievement of a third performance milestone; provided, however, that such achievement occurs by June 30, 2022 and Mr. Hindman remains employed with us through each applicable vesting date. The performance milestones applicable to Mr. Hindman's performance-contingent RSUs are as follows:

<table>
<thead>
<tr>
<th>Performance Milestone</th>
<th>#1 Successful Completion of a BD Transaction(1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>#2</td>
<td>Achieve additional sell-side analyst coverage(2)</td>
</tr>
<tr>
<td>#3</td>
<td>Achieve a more diversified shareholder base(3)</td>
</tr>
</tbody>
</table>

(1) “Successful Completion of a BD Transaction” means the execution of a definitive agreement for the out-license of a Company-discovered compound which provides for total upfront and potential milestone payments and/or purchases of the Company's equity securities at or above market prices of at least $250 million in aggregate.
The compensation committee certification of the milestone described above for the Five-Year Performance RSAs for the second successful completion of a BD transaction triggered the initial vesting of one-third of the performance-contingent RSUs granted to Mr. Hindman.

Post-Termination Protection

We believe that the possibility of a change in control creates uncertainty for our officers regarding their continued employment because such transactions frequently result in senior management changes. We provide change in control protections to our officers to alleviate concerns regarding the possible occurrence of such a transaction, allowing them to focus their attention on our business in a highly competitive labor market. In addition, these protections encourage executives to remain with us during the threat or negotiation of a change in control transaction, which preserves our value and the potential benefit to be received by our shareholders in the transaction. No new agreements with our named executive officers covering potential payments upon termination or change-in-control were entered into during 2019, nor were there any amendments to such existing named executive officer agreements.

The change in control severance benefits are structured under a plan instead of individual employment agreements. With this change in control severance plan, we sought uniformity of results among the officers based on their positions. In addition, we believe that the events triggering payment, both the consummation of a change in control and an involuntary termination, and then only when there is no misconduct by the officer, are fair hurdles for the ensuing income protection. A description of our change in control severance plan is in the “Potential Payments Upon Termination or Change-in-Control” section on page 49. For officers who were eligible to participate in the Amended and Restated Change in Control Severance Plan of Innoviva, Inc. (“Innoviva”) prior to our spin-off from Innoviva in 2014 (i.e., such named executive officer was an officer of Innoviva as of December 16, 2009), we provide gross-ups for excise taxes potentially due upon a change in control. This provides former Innoviva employees a level of benefits that is at least equal to those they were eligible for prior to our spin-off.

We do not have agreements providing severance in the event of involuntary terminations that do not occur in connection with a change in control with any of our officers except the CEO. Pursuant to the offer letter we entered into with Mr. Winningham to become our CEO, if Mr. Winningham's service is terminated without cause, he will receive a lump-sum severance payment of 24 months of his current salary plus two times his current target bonus.

Perquisites

We do not provide a non-qualified deferred compensation program or a supplemental executive retirement plan to our named executive officers. We generally do not provide perquisites or other personal benefits to named executive officers that we do not provide to all of our employees. However,
during 2019, we provided Mr. Hindman with a cash signing bonus in the amount of $175,000 which was negotiated at the time of his hiring, and which is repayable in full if he resigns from his employment with us within the first two years of his employment. We also pay Dr. Haumann a cost of living stipend in connection with his relocation to the United States that resulted from his transfer of employment from Theravance Biopharma UK Limited to Theravance Biopharma US, Inc.

Tax Deductibility of Pay

Section 162(m) of the Internal Revenue Code of 1986, as amended, places a limit of $1,000,000 on the amount of compensation that we may deduct in any one year with respect to our CEO and certain other executive officers. Prior to changes in tax law taking effect in 2018, there was an exception to the $1,000,000 limitation for performance-based compensation, including options, meeting certain requirements. Historically some of our named executive officer compensation arrangements were intended to qualify for this exception. The exemption from the Section 162(m) deduction limit for performance-based compensation has been repealed, effective for taxable years beginning after December 31, 2017. As a result of the repeal of the performance-based compensation exemption, Section 162(m) is no longer a significant factor in compensation decisions and compensation paid to our CEO and certain other executive officers in excess of $1,000,000 will not be deductible unless it qualifies for transition relief applicable to certain arrangements in place as of November 2, 2017.

Compensation Committee Report(1)

The compensation committee has reviewed and discussed the foregoing Compensation Discussion and Analysis with management and, based on such review and discussions, the compensation committee has recommended to the board of directors that the Compensation Discussion and Analysis be included in this proxy statement.

Submitted by the following members of the compensation committee:

Eran Brosby
Peter S. Ringrose, Ph.D.
George M. Whitesides, Ph.D.
William D. Young, Chairman

(1) The material in this report is not "soliciting material," is not deemed "filed" with the SEC and is not to be incorporated by reference in any filing of Theravance Biopharma under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.
The following table sets forth all of the compensation awarded to, earned by, or paid to our “principal executive officer,” our “principal financial officer” and our next three most highly compensated executive officers (our “named executive officers”) for our fiscal years ended December 31, 2019, 2018 and 2017, as applicable.

<table>
<thead>
<tr>
<th>Name and Principal Position</th>
<th>Year</th>
<th>Salary ($)(1)</th>
<th>Bonus ($)</th>
<th>Share Awards ($)(2)</th>
<th>Option Awards ($)(2)</th>
<th>Non-Equity Incentive Plan Compensation ($)(3)</th>
<th>All Other Compensation ($)</th>
<th>Total ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick E. Winningham</td>
<td>2019</td>
<td>983,710</td>
<td>—</td>
<td>4,469,300</td>
<td>473,906</td>
<td>5,496(4)</td>
<td>5,932,411</td>
<td>5,932,411</td>
</tr>
<tr>
<td>Chief Executive Officer</td>
<td>2018</td>
<td>956,600</td>
<td>74,767</td>
<td>796,320</td>
<td>690,154</td>
<td>5,000</td>
<td>2,522,841</td>
<td>2,522,841</td>
</tr>
<tr>
<td></td>
<td>2017</td>
<td>932,534</td>
<td>201,997</td>
<td>874,720</td>
<td>302,995</td>
<td>5,000</td>
<td>2,317,245</td>
<td>2,317,245</td>
</tr>
<tr>
<td>Andrew A. Hindman(5)</td>
<td>2019</td>
<td>315,000</td>
<td>175,000(6)</td>
<td>847,000</td>
<td>216,000</td>
<td>—</td>
<td>3,757,956</td>
<td>3,757,956</td>
</tr>
<tr>
<td>Senior Vice President and Chief Financial Officer</td>
<td>2018</td>
<td>497,810</td>
<td>34,125</td>
<td>255,960</td>
<td>315,000</td>
<td>414,300</td>
<td>1,517,194</td>
<td>1,517,194</td>
</tr>
<tr>
<td>Brett Haumann(7)</td>
<td>2019</td>
<td>543,047</td>
<td>—</td>
<td>1,708,850</td>
<td>70,000(10)</td>
<td>42,382</td>
<td>2,464,280</td>
<td>2,464,280</td>
</tr>
<tr>
<td>Senior Vice President, Clinical Development and Chief Medical Officer</td>
<td>2018</td>
<td>506,374</td>
<td>32,914</td>
<td>255,960</td>
<td>303,824</td>
<td>5,973</td>
<td>1,105,046</td>
<td>1,105,046</td>
</tr>
<tr>
<td>Frank Pasqualone</td>
<td>2019</td>
<td>520,299</td>
<td>16,374(9)</td>
<td>1,708,850</td>
<td>208,626</td>
<td>7,097(10)</td>
<td>2,461,246</td>
<td>2,461,246</td>
</tr>
<tr>
<td>Senior Vice President and Chief Commercial Operations Officer</td>
<td>2018</td>
<td>506,374</td>
<td>32,914</td>
<td>255,960</td>
<td>303,824</td>
<td>5,973</td>
<td>1,105,046</td>
<td>1,105,046</td>
</tr>
<tr>
<td></td>
<td>2017</td>
<td>505,145</td>
<td>45,574</td>
<td>281,160</td>
<td>68,360</td>
<td>6,020</td>
<td>906,259</td>
<td>906,259</td>
</tr>
<tr>
<td>Bradford J. Shafer</td>
<td>2019</td>
<td>537,403</td>
<td>—</td>
<td>1,708,850</td>
<td>215,611</td>
<td>6,983(11)</td>
<td>2,468,848</td>
<td>2,468,848</td>
</tr>
<tr>
<td>Executive Vice President, General Counsel and Secretary</td>
<td>2018</td>
<td>518,080</td>
<td>33,770</td>
<td>255,960</td>
<td>311,726</td>
<td>5,000</td>
<td>1,124,537</td>
<td>1,124,537</td>
</tr>
<tr>
<td></td>
<td>2017</td>
<td>500,561</td>
<td>90,356</td>
<td>281,160</td>
<td>135,533</td>
<td>5,000</td>
<td>1,012,609</td>
<td>1,012,609</td>
</tr>
<tr>
<td>Renee D. Gala(12)</td>
<td>2019</td>
<td>3,604</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>9,654</td>
<td>9,654</td>
</tr>
<tr>
<td>Former Senior Vice President and Chief Financial Officer, Treasurer</td>
<td>2018</td>
<td>473,085</td>
<td>30,919</td>
<td>235,960</td>
<td>285,407</td>
<td>5,000</td>
<td>1,050,371</td>
<td>1,050,371</td>
</tr>
<tr>
<td></td>
<td>2017</td>
<td>443,305</td>
<td>80,020</td>
<td>281,160</td>
<td>120,031</td>
<td>5,000</td>
<td>929,516</td>
<td>929,516</td>
</tr>
</tbody>
</table>

(1) Includes amounts deferred pursuant to our 401(k) plan.

(2) The amounts in these columns reflect the aggregate grant date fair value of share awards and option awards granted by us, computed in accordance with FASB ASC Topic 718. See Notes 1 and 11 of the notes to our consolidated financial statements in our Annual Report on Form 10 K filed on February 28, 2019 for a discussion of all assumptions made by us in determining the grant date fair value of such awards. In accordance with SEC rules, the grant date fair value of any award subject to a performance condition is based on the probable outcome of the performance conditions. In addition to the awards reflected in these columns, Mr. Hindman was granted a performance-contingent RSU in July 2019, the vesting of which is tied to the achievement of performance milestones, as described in greater detail in the “2019 Equity Awards Granted to Mr. Hindman” section of the “Compensation Discussion and Analysis” beginning on page 41. At the time the award was made it was not probable that any of the performance milestones would be achieved and therefore no amount attributable to the award is included in the “share awards” column. The grant date fair value of the award assuming that all three milestones (the maximum for purposes of full vesting of the RSUs) will be achieved was $1,016,400.

(3) The amounts in this column reflect cash bonus awards earned by the named executive officers under our annual cash bonus plan, and which were paid in the first quarter of the following year.

(4) Consists of (i) $496, which was the value of a gift received at a sales event, plus tax gross-up amounts associated therewith, which was provided for all employees who received a gift at the event and (ii) matching contributions for the 401(k) plan of $5,000.

(5) Mr. Hindman was hired in 2019. Accordingly, compensation information is not provided for 2017 or 2018.
(6) Consists of a signing bonus of $175,000 that was paid to Mr. Hindman in connection with his commencement of employment and which is subject to repayment in the event he terminates employment with us prior to the second anniversary of his date of hire.

(7) Dr. Haumann was employed by us, but was not one of our named executive officers in 2017. Accordingly, compensation information is only provided for 2018 and 2019.

(8) Consists of (i) a cost of living stipend of $42,000 paid to Dr. Haumann in 2018 in connection with his transfer of employment from Theravance Biopharma UK Limited to Theravance Biopharma US, Inc. in 2018; and (ii) $382, which was the value of a gift received at a sales event, plus tax gross-up amounts associated therewith, which was provided for all employees who received a gift at the event.

(9) Reflects a cash bonus awarded to Mr. Pasqualone at the discretion of the compensation committee, as discussed in greater detail in the “Annual Cash Incentive Compensation” section of the “Compensation Discussion and Analysis” beginning on page 36.

(10) Consists of (i) $1,654, which was the value of a gift received at a sales event, plus tax gross-up amounts associated therewith, which was provided for all employees who received such gifts and (ii) matching contributions for the 401(k) plan of $5,000.

(11) Consists of (i) $1,983, which was the value of a gift received as a service award for years served at the company, plus tax gross-up amounts associated therewith, which was provided for all employees who received such gifts and (ii) matching contributions for the 401(k) plan of $5,000.

(12) Ms. Gala resigned as an employee on January 2, 2019 and provided transition consulting services through February 28, 2019.

(13) Consists of (i) $1,050, which was the value of a gift received at a sales event, plus tax gross-up amounts associated therewith and (ii) matching contributions for the 401(k) plan of $5,000.

2019 Grants of Plan-Based Awards

The following table sets forth each non-equity incentive plan award and equity incentive plan awards granted to our named executive officers during fiscal year 2019. Unless indicated below, all equity awards were made under our 2013 Equity Incentive Plan. As a result of her resignation in January 2, 2019, Ms. Gala did not receive any incentive plan awards during fiscal year 2019.

<table>
<thead>
<tr>
<th>Name</th>
<th>Grant Date</th>
<th>Target (1)</th>
<th>Maximum ($)</th>
<th>Threshold (9)</th>
<th>Target (9)</th>
<th>All Other Option Awards: Number of Securities Underlying Options (9)(2)</th>
<th>All Other Stock Awards: Number of Shares or Units (9)(2)</th>
<th>Exercise or Base Price of Option Awards ($/sh)</th>
<th>Grant Date Fair Value of Stock Awards ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick E. Winningham</td>
<td>2/5/2019</td>
<td>392,382</td>
<td>888,574</td>
<td>—</td>
<td>—</td>
<td>170,000(3)</td>
<td>—</td>
<td>—</td>
<td>4,468,956</td>
</tr>
<tr>
<td>Andrew A. Hindman</td>
<td>7/1/2019</td>
<td>270,000</td>
<td>405,000</td>
<td>—</td>
<td>—</td>
<td>260,000(4)</td>
<td>—</td>
<td>16.94</td>
<td>2,204,956</td>
</tr>
<tr>
<td></td>
<td>7/1/2019</td>
<td>—</td>
<td>—</td>
<td>50,000(5)</td>
<td>—</td>
<td>847,000</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>7/1/2019</td>
<td>—</td>
<td>—</td>
<td>20,000(6)</td>
<td>60,000(6)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Brett Haumann</td>
<td>N/A</td>
<td>272,344</td>
<td>408,516</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>2/5/2019</td>
<td>—</td>
<td>—</td>
<td>65,000(3)</td>
<td>—</td>
<td>1,708,850</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Frank Pasqualone</td>
<td>N/A</td>
<td>260,783</td>
<td>391,174</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>2/5/2019</td>
<td>—</td>
<td>—</td>
<td>65,000(3)</td>
<td>—</td>
<td>1,708,850</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Bradford J. Shafer</td>
<td>N/A</td>
<td>269,514</td>
<td>404,270</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>2/5/2019</td>
<td>—</td>
<td>—</td>
<td>65,000(3)</td>
<td>—</td>
<td>1,708,850</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

(1) Each named executive officer was granted a non-equity incentive plan award pursuant to our 2019 annual cash bonus plan which is discussed in greater detail in the “Annual Cash Incentive Compensation” section of the “Compensation Discussion and Analysis” beginning on page 36. The amounts shown in the “target” column reflect the target payout under the plan.
Outstanding Equity Awards at 2019 Fiscal Year-End

The following table sets forth information regarding each unexercised option to purchase our ordinary shares, each restricted share unit and each restricted ordinary share held by each of our named executive officers as of December 31, 2019.

(2) The RSUs and Options will become fully vested if we are acquired and the holder is subject to an involuntary termination. Such vesting acceleration is described in greater detail in "Potential Payments Upon Termination or Change in Control" beginning on page 49.

(3) Reflects an annual replenishment RSU granted under our 2013 Equity Incentive Plan. Twenty five percent of the RSUs vested on February 20, 2020 and the remaining 75% of the RSUs vest in equal quarterly installments over the next four years, provided the holder remains in continuous service through each vesting date.

(4) In connection with Mr. Hindman's commencement of employment with us, he was granted an option under our 2013 Equity Incentive Plan. 25% of the shares subject to the option will vest on July 1, 2020 and the remaining shares vest monthly thereafter, subject to Mr. Hindman's continuous service through each vesting date.

(5) In connection with Mr. Hindman's commencement of employment with us, he was granted RSUs under our 2013 Equity Incentive Plan. 25% of the RSUs vest on August 20th of each of 2020, 2021, 2022, and 2023 subject to Mr. Hindman's continuous service through each vesting date.

(6) In connection with Mr. Hindman's commencement of employment with us, he was granted performance-contingent RSUs under our Performance Incentive Plan. Vesting of these RSUs is contingent upon the achievement of performance milestones as well as continuous employment, as described in greater detail in the "2019 Equity Awards Granted to Mr. Hindman" section of the "Compensation Discussion and Analysis" beginning on page 41. The number of shares reflected in the table above as the "threshold" payout assumes that one of the performance milestones will be achieved and Mr. Hindman will remain employed through the next regularly scheduled quarterly vest date after such achievement. The number of shares reflected in the table above as the "target" payout assumes that all three of the milestones will be achieved and that Mr. Hindman will remain employed by the Company through for a twelve month period thereafter, through the next regularly scheduled quarterly vest date. No "maximum" is applicable to these awards, as full vesting of the performance-contingent RSUs will be achieved at the "target" payout in the table above. In the event we are acquired prior to December 31, 2022 and the performance milestones applicable to any remaining unvested performance-contingent RSUs have not yet been achieved, a portion of such unvested RSUs may be forfeited if the transaction value is not at least two times our closing share price on the date the Mr. Hindman's performance-contingent RSUs were granted. Any then-remaining performance-contingent RSUs will be eligible for full vesting acceleration if Mr. Hindman is subject to an involuntary termination in connection with such acquisition. Such vesting acceleration is described in greater detail in "Potential Payments Upon Termination or Change in Control" beginning on page 49.

(7) At the time the performance-contingent RSUs were granted to Mr. Hindman, it was not probable that any of the performance milestones relative to such award would be achieved. The grant date fair value of the award assuming that both milestones are achieved (the highest level attainable for purposes of full vesting of the RSUs) is set forth in footnote 3 to the Summary Compensation Table on page 44.
either Innoviva or us following the spin-off. As a result of her resignation in January 2, 2019, Ms. Gala did not have any outstanding equity awards as of December 31, 2019.

<table>
<thead>
<tr>
<th>Name</th>
<th>Option Awards</th>
<th>Stock Awards</th>
<th>Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (f)</th>
<th>Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick E Winningham</td>
<td>TRPH 38,000(1)</td>
<td>TRPH 320,000(1)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 23,51</td>
<td>TRPH 8/2/2024</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 70,000(5)</td>
<td>TRPH 1,812,380</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 147,000(6)</td>
<td>TRPH 3,805,830</td>
<td>168,000(6)</td>
<td>4,349,520</td>
</tr>
<tr>
<td></td>
<td>TRPH 8,758(7)</td>
<td>TRPH 226,538</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 15,756(8)</td>
<td>TRPH 407,768</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 17,008(9)</td>
<td>TRPH 4,461,380</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Andrew A. Hindman</td>
<td>TRPH 260,000(10)</td>
<td>TRPH 56,000(11)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 16.94</td>
<td>TRPH 6/30/2029</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 517,800</td>
<td>TRPH 20,000(12)</td>
<td>517,800</td>
<td>—</td>
</tr>
<tr>
<td>Brent Haumann</td>
<td>INVA 94,823(13)</td>
<td>TRPH 59,375(1)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 29.95</td>
<td>TRPH 12/1/2023</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 22,500(5)</td>
<td>TRPH 582,525</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 47,256(6)</td>
<td>TRPH 1,223,383</td>
<td>54,000(6)</td>
<td>1,398,060</td>
</tr>
<tr>
<td></td>
<td>TRPH 2,812(7)</td>
<td>TRPH 72,803</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 5,062(8)</td>
<td>TRPH 131,055</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 65,000(9)</td>
<td>TRPH 1,682,850</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Frank Pasqualone</td>
<td>INVA 189,647(14)</td>
<td>TRPH 100,000(3)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 30.25</td>
<td>TRPH 1/22/2024</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 22,500(5)</td>
<td>TRPH 582,525</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 47,256(6)</td>
<td>TRPH 1,223,383</td>
<td>54,000(6)</td>
<td>1,398,060</td>
</tr>
<tr>
<td></td>
<td>TRPH 2,812(7)</td>
<td>TRPH 72,803</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 5,062(8)</td>
<td>TRPH 131,055</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 65,000(9)</td>
<td>TRPH 1,682,850</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Bradford J. Shafer</td>
<td>TRPH 170,000(15)</td>
<td>TRPH 28.75</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 15,625(16)</td>
<td>TRPH 40,440</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 22,500(5)</td>
<td>TRPH 582,525</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 47,256(6)</td>
<td>TRPH 1,223,383</td>
<td>54,000(6)</td>
<td>1,398,060</td>
</tr>
<tr>
<td></td>
<td>TRPH 2,812(7)</td>
<td>TRPH 72,803</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 5,062(8)</td>
<td>TRPH 131,055</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>TRPH 65,000(9)</td>
<td>TRPH 1,682,850</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

(1) Computed in accordance with SEC rules as the number of unvested RSUs or RSAs, as applicable, multiplied by the closing market price of our ordinary shares at the end of our 2019 fiscal year, which was $25.89. The actual value (if any) to be realized by the officer depends on whether the shares vest and the future performance of our ordinary shares.

(2) Computed in accordance with SEC rules as the number of unvested RSUs or RSAs multiplied by the closing market price of our ordinary shares at the end of the 2019 fiscal year, which was $25.89. The actual value (if any) to be realized by the officer depends on whether the performance milestones related thereto are achieved, whether the award vests following achievement of the performance milestones, and the future performance of our ordinary shares.

(3) Messrs. Winningham and Pasqualone and Dr. Haumann were each granted options under our 2013 Equity Incentive Plan on June 3, 2014 in connection with their commencement of employment with us. Twenty-five percent of the shares subject to the option vested on February 20, 2015 and the remaining shares vested monthly thereafter over the course of the next three years, subject to the officer's continuous service through each vesting date.

(4) Mr. Winningham was granted an option under our 2013 Equity Incentive Plan on August 22, 2014 in connection with commencing full-time employment with us. Twenty-five percent of the shares subject to the option vested on August 15, 2015 and the remaining shares vested monthly thereafter over the course of the next three years, subject to Mr. Winningham's continuous service through each vesting date.

(5) Messrs. Winningham, Pasqualone and Shafer and Dr. Haumann were each granted an annual replenishment equity award grant of RSUs under our 2013 Equity Incentive Plan on March 15, 2016. Twenty percent of the RSUs vested on February 28, 2017 and the
remaining 80% of the RSUs vest in equal quarterly installments over the following four years, subject to the officer's continuous service through each vesting date.

(6) Messrs. Winningham, Pasqualone and Shafer each received performance contingent RSAs and Dr. Haumann received performance-contingent RSUs under our 2013 Equity Incentive Plan on March 15, 2016, which we refer to as "Five-Year Performance RSAs." The vesting of these RSAs (or, in the case of Dr. Haumann, RSUs) is contingent upon the achievement of performance milestones by December 31, 2020 as well as continued employment, as described in detail in the "2016 Five-Year Performance RSAs" section of the "Compensation Discussion and Analysis" beginning on page 41 of our Proxy Statement for 2017 Annual General Meeting of Shareholders filed on April 11, 2017. In 2019, a sufficient number of milestones adding up to fifteen points was achieved and an additional 35% of the shares subject to the awards became eligible to vest on February 20, 2020 (subject to the officer's continued employment through such date), which are reflected in column (g) and (h). In accordance with SEC rules, the number of shares in column (i) and the value of those shares in column (j) reflects the next possible payout assuming milestones that add up to at least twenty points are achieved.

(7) Messrs. Winningham, Pasqualone and Shafer and Dr. Haumann were each granted an annual replenishment equity award of RSUs under our 2013 Equity Incentive Plan on February 6, 2017. Twenty-five percent of the RSUs vested on February 20, 2018 and the remaining 75% vest in equal quarterly installments over the following three years, subject to the officer's continuous service through each vesting date.

(8) Messrs. Winningham, Pasqualone and Shafer and Dr. Haumann were each granted an annual replenishment equity award of RSUs under our 2013 Equity Incentive Plan on February 12, 2018. Twenty-five percent of the RSUs vested on February 20, 2019 and the remaining 75% vest in equal quarterly installments over the following three years, subject to the officer's continuous service through each vesting date.

(9) Messrs. Winningham, Pasqualone and Shafer and Dr. Haumann were each granted an annual replenishment equity award of RSUs under our 2013 Equity Incentive Plan on February 6, 2017. Twenty-five percent of the RSUs vested on February 20, 2018 and the remaining 75% vest in equal quarterly installments over the following three years, subject to the officer's continuous service through each vesting date.

(10) In connection with Mr. Hindman's commencement of employment with us, he was granted an option under our Performance Incentive Plan. 25% of the shares subject to the option will vest on July 1, 2020 and the remaining shares vest monthly thereafter, subject to Mr. Hindman's continuous service through each vesting date.

(11) In connection with Mr. Hindman's commencement of employment with us, he was granted RSUs under our 2013 Equity Incentive Plan. 25% of the RSUs vested on August 20th of each of 2020, 2021, 2022, and 2023 subject to Mr. Hindman's continuous service through each vesting date.

(12) In connection with Mr. Hindman's commencement of employment with us, he was granted performance-contingent RSUs under our Performance Incentive Plan. Vesting of these RSUs is contingent upon the achievement of performance milestones as well as continued employment, as described in greater detail in the "2019 Equity Awards Granted to Mr. Hindman" section of the "Compensation Discussion and Analysis" beginning on page 41. The first performance milestone applicable to Mr. Hindman's performance-contingent RSUs was achieved in 2019 and one-third of such RSUs vested in 2020 upon certification of such milestone. The shares that vested in 2020 upon such certification are reflected in columns (g) and (h). In accordance with SEC rules, the number of shares in column (i) and the value of those shares in column (j) reflects payout of the performance-contingent RSUs assuming the second milestone is achieved.

(13) Dr. Haumann was granted an option by Innoviva under its 2012 Equity Incentive Plan on December 2, 2013 in connection with his commencement of employment with Innoviva. Twenty-five percent of the shares subject to the option vested on February 20, 2015 and the remaining shares vest monthly thereafter over the course of the next three years, subject to Dr. Haumann's continuous service with the Company through each vesting date.

(14) Mr. Pasqualone was granted an option by Innoviva under its 2012 Equity Incentive Plan on January 23, 2014 in connection with his commencement of employment with Innoviva. Twenty-five percent of the shares subject to the option vested on February 3, 2015 and the remaining shares vest monthly thereafter over the course of the next three years, subject to Mr. Pasqualone's continuous service with the Company through each vesting date.

(15) Mr. Shafer was granted an option under our 2013 Equity Incentive Plan on September 8, 2014 in connection with his commencement of employment with us. Twenty-five percent of the shares subject to the option vested on September 1, 2015 and the remaining shares vested monthly thereafter over the course of the next three years, subject to Mr. Shafer's continuous service through each vesting date.

(16) Mr. Shafer was granted RSUs under our 2013 Equity Incentive Plan on March 15, 2016 in connection with his promotion to Executive Vice President, General Counsel and Secretary. Twenty-five percent of the RSUs vested on February 20, 2017 and the remaining 75% of the RSUs vest in equal quarterly installments over the next three years, subject to Mr. Shafer's continuous service through each vesting date.
2019 Option Exercises and Stock Vested

The following table shows the number of restricted ordinary shares and restricted share units held by each named executive officer that vested during the 2019 fiscal year. None of our named executive officers exercised any options during the 2019 fiscal year.

<table>
<thead>
<tr>
<th>Name</th>
<th>Security</th>
<th>Number of Shares Acquired on Vesting (#)</th>
<th>Value Realized on Vesting ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick E Winningham</td>
<td>TBPH</td>
<td>90,875</td>
<td>2,067,750</td>
</tr>
<tr>
<td>Andrew A. Hindman</td>
<td>TBPH</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Brett Haumann</td>
<td>TBPH</td>
<td>32,625</td>
<td>756,833</td>
</tr>
<tr>
<td>Frank Pasqualone</td>
<td>TBPH</td>
<td>33,741</td>
<td>786,965</td>
</tr>
<tr>
<td></td>
<td>INVA</td>
<td>5,000</td>
<td>79,600</td>
</tr>
<tr>
<td>Bradford J. Shafer</td>
<td>TBPH</td>
<td>37,938</td>
<td>865,825</td>
</tr>
<tr>
<td>Renee D. Gala</td>
<td>TBPH</td>
<td>15,749</td>
<td>425,223</td>
</tr>
</tbody>
</table>

(1) Value realized is based on the fair market value of our ordinary shares on the vesting date (or, in the case of vesting of Innoviva RSAs held by one of our named executive officers, based on the fair market value of Innoviva's common stock) multiplied by the number of shares vested and does not necessarily reflect proceeds received by the officer. With respect to vesting of Innoviva RSAs, the value also includes cash dividends previously declared with respect to such RSAs, which were also released to the holder upon vesting of the RSA.

Potential Payments Upon Termination or Change-in-Control

Each of our named executive officers is entitled to severance benefits pursuant to our severance plan. In addition, Mr. Winningham is entitled to severance benefits pursuant to his letter agreement entered into in connection with his appointment as Chief Executive Officer.

Change in Control Severance Benefits

Pursuant to our severance plan, if a named executive officer is subject to an involuntary termination within 3 months prior to or 24 months after our change in control, the officer is entitled to the following benefits provided he or she signs a release of claims:

- In the case of our Senior Vice Presidents and Executive Vice President, a lump sum payment equal to 150% of the officer's annual base salary and target bonus.
- In the case of our Chief Executive Officer, a lump sum payment equal to 200% of the officer's annual base salary and target bonus.
- A pro-rata portion of the named executive officer's target bonus based on the number of full months of employment completed in the year of termination.
- Continuation of the officer's health and welfare benefits for the shorter of 18 months or the expiration of the officer's continuation coverage under COBRA.
- Full vesting of any unvested options or other equity awards held by the officer; provided, however, that the restricted ordinary shares (or, in the case of Dr. Haumann, the RSUs) subject to performance-based vesting that were granted to our named executive officers on March 15,
2016 (the "Five-Year Performance RSAs") as well as the performance-based RSUs granted to Mr. Hindman on July 1, 2019 (the "Hindman PRSUs") for which the performance milestones have not been achieved as of the change in control (the "Remaining Shares") are subject to forfeiture at the time of the change in control as follows: (i) if the per share value to be received by a holder of our ordinary shares in such change in control (the "CIC Value") is less than or equal to $16.96 per share or, in the case of Mr. Hindman, $16.94 per share, as adjusted for share splits and similar events (such amount, in either case, the "Base Value"), all Remaining Shares will be forfeited; (ii) if the CIC Value is greater than the Base Value but less than two times the Base Value, then a percentage of each named executive officer's Remaining Shares equal to the percentage by which the CIC Value is greater than the Base Value (rounded down to the nearest whole percent) may be retained by the named executive officer and the balance of the Remaining Shares will be forfeited; and (iii) if the CIC Value is equal to or greater than two times the Base Value, none of the Remaining Shares will be forfeited. All unforfeited Remaining Shares following such change in control will be subject to the following vesting schedule and will remain eligible for vesting acceleration in accordance with our Change in Control and Severance Plan: Fifty percent of the unforfeited Remaining Shares will vest on the one-year anniversary of the change in control and the remaining 50% of the unforfeited Remaining Shares will vest on the two-year anniversary of the change in control, subject to the named executive officer's continuous service through the applicable vesting date.

• In the case of named executive officers who were eligible to participate in the Theravance, Inc. Amended and Restated Change in Control Severance Plan (i.e., such named executive officer was an officer of Innoviva as of December 16, 2009), a tax gross-up payment in the event an independent accounting firm selected by us determines that the named executive officer would be subject to excise taxes under IRC Section 4999 as a result of payments under the change in control severance plan or otherwise.

Definitions

A "change in control" for purposes of our change in control severance plan includes:

• The consummation of a merger or consolidation if persons who were not our shareholders prior to the merger or consolidation own 50% or more of the voting securities of the surviving company and its parent.

• A sale, transfer or other disposition of all or substantially all of our assets.

• A change in the composition of our board of directors as a result of which fewer than 50% of the incumbent directors either were directors on the date twelve months prior to the change in control (the "Original Directors") or were appointed or nominated for election to the board of directors by a majority of the Original Directors or directors whose appointment or nomination was approved by at least 50% of the Original Directors.

• A transaction as a result of which any person becomes the beneficial owner of 50% or more of our outstanding voting securities.

A transaction shall not constitute a change in control if its sole purpose is to change our country or state of incorporation, as applicable, or to create a holding company that will be owned in substantially the same proportions by the persons who held our securities immediately before such transaction. In addition, a transaction shall not constitute a change in control unless it also constitutes a "change in control event" under Treasury Regulation 1.409A-3(a)(5).

An "involuntary termination" for purposes of our change in control severance plan means a termination of an officer's employment for reasons other than misconduct, or an officer's resignation following (1) a material diminution in the officer's authority, duties or responsibilities, (2) a material
reduction in the officer's base compensation, (3) a material change in the officer's work location or (4) a material breach of the officer's employment agreement by us. In order to qualify as an involuntary termination, the officer must give written notice to us within 90 days after the initial existence of one of the conditions described above and such condition must not have been cured within 30 days thereafter.

“Misconduct” for purposes of our change in control severance plan means an officer's (1) commission of any material act of fraud, embezzlement or dishonesty, (2) material unauthorized use or disclosure of confidential information or trade secrets or (3) other material intentional misconduct adversely affecting our business or affairs.

**Severance Benefits**

In addition to the severance benefits he is entitled to pursuant to our change in control severance plan, Mr. Winningham's offer letter provides that if his employment is terminated by us without cause and he is not eligible for severance benefits under our change in control severance plan, he will receive a lump-sum severance payment of 24 months' salary plus two times his current target bonus provided he signs a general release of claims. "Cause" means Mr. Winningham's (i) unauthorized use or disclosure of our confidential information or trade secrets, which use causes material harm to us, (ii) conviction of a felony under the laws of the U. S. or any state thereof, (iii) gross negligence, or (iv) repeated failure to perform lawful assigned duties for thirty days after receiving written notification from our board of directors.

The table below reflects the potential payments and benefits to which our named executive officers would be entitled under the arrangements described above. The amounts shown in the table below assume that both the change in control (if applicable) and termination of employment occurred on December 31, 2019 (the last business day of the 2019 fiscal year) and that all eligibility requirements under the change in control severance plan (or in the case of Mr. Winningham, pursuant to his offer letter) were met. Although Messrs. Winningham and Shafer would be eligible for a tax gross-up payment pursuant to the change in control severance plan as described above, a change in control as of December 31, 2019 would not have resulted in potential payments or benefits to either that would have triggered excise taxes under IRC Section 4999 and a gross-up amount is therefore not included in the table below.

The following assumptions were used in calculating the values described in the table below:

* **Value of Option Acceleration:** The value of the vesting acceleration was calculated by multiplying the number of unvested option shares by the difference between the closing price of our ordinary shares on December 31, 2019 (which was $25.89 per share) and the exercise price of the option.

* **Value of Restricted Ordinary Shares and Restricted Share Unit Acceleration:** The value of the vesting acceleration of the restricted ordinary shares and unvested RSUs was calculated by
multiplying the number of unvested shares or RSUs by the closing price of our ordinary shares on December 31, 2019 (which was $25.89 per share).

Pay Ratio Disclosure

As required by the Dodd-Frank Act and SEC rules, we are providing the following information about the relationship of the annual total compensation of our employees and the annual total compensation of Rick Winningham, our Chief Executive Officer:

For our fiscal year ended December 31, 2019:

- The annual total compensation of the employee who was determined last year to be our median employee was $219,765; and
- The annual total compensation of our CEO, as reported in the 2019 Summary Compensation Table included elsewhere in this Proxy Statement, was $5,932,411.
- Based on this information the ratio of the annual total compensation of Mr. Winningham to that of our median employee was approximately 27:1.

The above ratio is appropriately viewed as an estimate. As there were no changes in our employee population or employee compensation arrangements in 2019 that we believe would significantly impact

<table>
<thead>
<tr>
<th>Name</th>
<th>Bonus for Year of Termination ($)</th>
<th>Cash Severance ($)</th>
<th>Vacation Payout ($)</th>
<th>Options that Vest ($)</th>
<th>Restricted Shares or RSUs that Vest ($)</th>
<th>Health and Welfare ($)</th>
<th>Total ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick E Winningham(6)</td>
<td>592,382</td>
<td>3,159,373</td>
<td>94,929</td>
<td>—</td>
<td>11,088,687</td>
<td>70,712</td>
<td>15,006,084</td>
</tr>
<tr>
<td>Andrew A. Hindman</td>
<td>270,000</td>
<td>1,215,000</td>
<td>18,172</td>
<td>2,327,000</td>
<td>2,115,216</td>
<td>42,809</td>
<td>5,988,197</td>
</tr>
<tr>
<td>Renee D. Gala(7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brett K. Haumann</td>
<td>272,344</td>
<td>1,225,549</td>
<td>52,372</td>
<td></td>
<td>3,832,341</td>
<td>11,561</td>
<td>5,394,167</td>
</tr>
<tr>
<td>Frank Pasqualone</td>
<td>260,783</td>
<td>1,173,521</td>
<td>50,149</td>
<td></td>
<td>3,832,341</td>
<td>42,809</td>
<td>5,359,602</td>
</tr>
<tr>
<td>Bradford J. Shafer</td>
<td>269,514</td>
<td>1,212,811</td>
<td>51,828</td>
<td></td>
<td>3,872,782</td>
<td>70,712</td>
<td>5,477,646</td>
</tr>
</tbody>
</table>

(1) Reflects payment of the officer's 2019 bonus at target.

(2) Reflects payment of 150% or 200% of the officer's base salary and target bonus, as applicable.

(3) Reflects full vesting of all unvested options.

(4) Reflects full vesting of all unvested RSAs and RSUs. It also includes vesting of 52% of the Remaining Shares, which is equal to the percentage by which the closing price of our ordinary shares on December 31, 2019, $25.89, is greater than the Base Value for the Five-Year Performance RSAs and the Hindman PRSUs, rounded down to the nearest whole percent. See “—Change in Control Severance Benefits” on page 49.

(5) Reflects the cost of each officer's COBRA premiums for 18 months.

(6) If Mr. Winningham's employment had been terminated by the Company without cause on December 31, 2019 other than in connection with a change in control, he would have been entitled to receive the cash severance payments indicated in column (c) and the vacation payout in column (d) but no other benefits.

(7) As a result of her termination of employment in early 2019, Ms. Gala did not receive the severance benefits described above. In connection with her resignation on January 2, 2019, Ms. Gala entered into a consulting agreement to facilitate the transition of activities following her departure through February 28, 2019. The sole compensation to Ms. Gala pursuant to the consulting agreement was continued vesting of certain of Ms. Gala's equity awards through the consulting period.
the required pay ratio disclosure, we used the same employee identified in 2018 and 2017 to identify the median of the annual compensation of our employees. We identified this employee by reviewing the Form W 2 compensation (specifically, Box 5 of such Form) of our U.S. employees as of December 31, 2017 for the period from January 1, 2017 through December 31, 2017. Non U.S. employees were excluded as they constituted less than 5% of our workforce. As of December 31, 2017, we had 340 employees, including nine employees in Ireland and one in the United Kingdom. No cost of living or other adjustments were made in determining our Median Employee. Once we identified our median employee, using the methodology described above, we determined that employee’s annual total compensation in accordance with the requirements of Item 402(c)(2)(x) of Regulation S-K for purposes of calculating the required pay ratio.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information known to us regarding beneficial ownership of our voting securities as of March 2, 2020 by:

- each person known by us to be the beneficial owner of more than 5% of any class of our voting securities;
- our named executive officers;
- each of our directors; and
- all executive officers and directors as a group.

Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Except as noted by footnote, and subject to community property laws where applicable, the persons named in the table below have sole voting and investment power with respect to all ordinary shares shown as beneficially owned by them. The table below is based upon information supplied by officers, directors, Forms 4 and 13F, and Schedules 13G and 13D filed with the SEC.

This table lists applicable percentage ownership based on 63,002,301 ordinary shares outstanding as of March 2, 2020. Options to purchase our ordinary shares that are exercisable within 60 days of March 2, 2020 and RSUs subject to release within 60 days of March 2, 2020 are deemed to be beneficially owned by the persons holding these options and RSUs, as applicable, for the purpose of computing percentage ownership of that person, but are not treated as outstanding for the purpose of computing any other person's ownership percentage.

<table>
<thead>
<tr>
<th>Name and Address of Beneficial Owner(1)</th>
<th>Number of Shares</th>
<th>Percent of Total Outstanding Ordinary Shares(2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GlaxoSmithKline plc(3)</td>
<td>9,644,808</td>
<td>15.3%</td>
</tr>
<tr>
<td>980 Great West Road</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brentford, Middlesex, TW8 9GS, United Kingdom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Baupost Group, L.L.C.(4)</td>
<td>9,309,168</td>
<td>14.8%</td>
</tr>
<tr>
<td>10 St. James Ave, Suite 1700</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boston, MA 02116</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BlackRock, Inc.(5)</td>
<td>8,682,679</td>
<td>13.8%</td>
</tr>
<tr>
<td>55 East 52nd Street</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New York, NY 10055</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FMR LLC(6)</td>
<td>8,524,173</td>
<td>13.5%</td>
</tr>
<tr>
<td>245 Summer Street</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boston MA 02210</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Link Fund Solutions Limited(7)</td>
<td>5,251,349</td>
<td>8.3%</td>
</tr>
<tr>
<td>6th Floor, 65 Gresham Street</td>
<td></td>
<td></td>
</tr>
<tr>
<td>London, EC2V 7NQ, United Kingdom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vanguard Group, Inc.(8)</td>
<td>4,003,602</td>
<td>6.4%</td>
</tr>
<tr>
<td>100 Vanguard Blvd.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malvern, PA 19355</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wellington Management Group LLP(9)</td>
<td>3,177,537</td>
<td>5.0%</td>
</tr>
<tr>
<td>c/o Wellington Management Company LLP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>280 Congress Street</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boston, MA 02210</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

54
## Beneficial Ownership

<table>
<thead>
<tr>
<th>Name and Address of Beneficial Owner(1)</th>
<th>Number of Shares</th>
<th>Percent of Total Outstanding Ordinary Shares(2)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Named Executive Officers and Directors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rick E Winningham(10)</td>
<td>1,433,672</td>
<td>2.3%</td>
</tr>
<tr>
<td>Andrew A. Hindman</td>
<td>12,940</td>
<td>*</td>
</tr>
<tr>
<td>Brett Haumann(11)</td>
<td>183,543</td>
<td>*</td>
</tr>
<tr>
<td>Bradford J. Shafer(12)</td>
<td>296,432</td>
<td>*</td>
</tr>
<tr>
<td>Frank Pasquaione(13)</td>
<td>374,420</td>
<td>*</td>
</tr>
<tr>
<td>Eran Broshy(14)</td>
<td>79,571</td>
<td>*</td>
</tr>
<tr>
<td>Robert V. Gunderson, Jr(15)</td>
<td>98,477</td>
<td>*</td>
</tr>
<tr>
<td>Burton G. Malkiel, Ph.D.(16)</td>
<td>116,142</td>
<td>*</td>
</tr>
<tr>
<td>Dean Mitchell(17)</td>
<td>79,571</td>
<td>*</td>
</tr>
<tr>
<td>Susan M. Molineaux, Ph.D.(18)</td>
<td>58,571</td>
<td>*</td>
</tr>
<tr>
<td>Donal O'Connor(19)</td>
<td>51,571</td>
<td>*</td>
</tr>
<tr>
<td>Peter S. Ringrose, Ph.D.(20)</td>
<td>73,999</td>
<td>*</td>
</tr>
<tr>
<td>Laurie Smaldone Alsup(21)</td>
<td>43,847</td>
<td>*</td>
</tr>
<tr>
<td>George M. Whitesides, Ph.D.(22)</td>
<td>268,613</td>
<td>*</td>
</tr>
<tr>
<td>William D. Young(23)</td>
<td>87,695</td>
<td>*</td>
</tr>
<tr>
<td>Renee D. Gala(24)</td>
<td>14,000</td>
<td>*</td>
</tr>
<tr>
<td>All executive officers and directors as a group (19 persons)(25)</td>
<td>3,801,694</td>
<td>5.9%</td>
</tr>
</tbody>
</table>

* Less than one percent.

(1) Unless otherwise indicated, the address for each beneficial owner is c/o Theravance Biopharma US, Inc., 901 Gateway Boulevard, South San Francisco, California 94080.

(2) Beneficial ownership as reported in the table has been determined in accordance with SEC rules and regulations and includes our ordinary shares that may be issued upon the exercise of options that are exercisable within 60 days of March 2, 2020 and RSUs subject to release within 60 days of March 2, 2020. Pursuant to SEC rules and regulations, all shares not currently outstanding that are subject to options exercisable within 60 days of March 2, 2020 and RSUs subject to release within 60 days of March 2, 2020 are deemed to be outstanding for the purpose of computing the "Percent of Class" held by the holder of the class but are not deemed to be outstanding for the purpose of computing the "Percent of Class" held by any other shareholder.

(3) Based on the Amendment No. 5 to Schedule 13D filed with the SEC on February 27, 2020 by GlaxoSmithKline plc. Shares are held of record by Glaxo Group Limited, an indirect wholly owned subsidiary of GlaxoSmithKline plc, an English public limited company. GlaxoSmithKline plc holds sole voting and sole dispositive power of 9,644,808 shares.

(4) Based on the Form 13F filed with the SEC on February 13, 2020 by Baupost Group, L.L.C./MA ("Baupost"). Baupost holds sole voting power of 9,309,168 shares.

(5) Based on the Amendment No. 6 to Schedule 13G filed with the SEC on March 9, 2020 by BlackRock, Inc. ("Blackrock"). Blackrock has sole voting power of 3,610,240 shares and sole dispositive power of 8,682,679 shares. The subsidiaries included in the report were as follows: BlackRock Advisors (UK) Limited and BlackRock Institutional Trust Company, National Association. The interest of LF Equity Income Fund and BlackRock Advisors (UK) Limited is each more than five percent of the total outstanding ordinary shares of Theravance Biopharma, Inc.

(6) Based on the Amendment No. 4 to Schedule 13G filed with the SEC on February 7, 2020 by FMR LLC ("FMR LLC") and Abigail P. Johnson, Director, the Chairman and the Chief Executive Officer of FMR LLC. FMR LLC has sole voting power of 1,367,618 shares and sole dispositive power of 8,524,173 shares. Ms. Johnson has sole dispositive power of 8,524,173 shares. FIAM LLC, and Fidelity Management & Research Company, a wholly owned subsidiary of FMR LLC ("FMR"
Co") beneficially owns the ordinary shares held by FMR LLC. FMR Co. beneficially owns 5% or greater of our ordinary shares. Members of the
Johnson family, including Ms. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC,
representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders'
voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares.
Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family
may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor
Ms. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the
Investment Company Act ("Fidelity Funds") advised by FMR Co., which power resides with the Fidelity Funds' Boards of Trustees. FMR Co. carries
out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees. The Amendment No. 4 to Schedule 13G
reflected the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and
other companies (collectively, the "FMR Reporters"). The Amendment No. 4 to Schedule 13G did not reflect securities, if any, beneficially owned by
certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and

(7) Based on the Schedule 13G filed with the SEC on October 29, 2019 by Link Fund Solutions Limited ("LFS"). LFS holds sole voting and dispositive
power of 5,251,349 shares. On October 15, 2019, when Woodford Investment Management Ltd was removed as investment manager of LF Woodford
Equity Income Fund ("WEIF"), the investment management role reverted to LFS in its capacity as the authorised corporate director of WEIF. Pursuant
to an agreement between WEIF and LFS, LFS has voting power over securities held of record by WEIF, including the Ordinary Shares.

(8) Based on the Amendment No. 3 to Schedule 13G filed with the SEC on February 12, 2020 by Vanguard Group, Inc. ("Vanguard"). Vanguard has sole
voting power of 94,787 shares, shared voting power of 6,911 shares, sole dispositive power of 3,909,110 shares and shared dispositive power of 94,402
shares. Vanguard Fiduciary Trust Company, a wholly-owned subsidiary of The Vanguard Group, Inc., is the beneficial owner of 87,581 shares or 0.15%
of the ordinary shares outstanding of the company as a result of its serving as investment manager of collective trust accounts. Vanguard Investments
Australia, Ltd., a wholly-owned subsidiary of The Vanguard Group, Inc., is the beneficial owner of 14,117 shares or 0.02% of the ordinary shares
outstanding of the company as a result of its serving as investment manager of Australian investment offerings.

(9) Based on the Schedule 13G filed with the SEC on January 28, 2020 by Wellington Management Group LLP, Wellington Group Holdings LLP,
Wellington Investment Advisors Holdings LLP, Wellington Management Company LLP, Wellington Management Group LLP, Wellington Group
Holdings LLP, and Wellington Investment Advisers Holdings LLP each has shared voting power of 3,045,226 shares and shared dispositive power of
3,177,537 shares. Wellington Management Company LLP has shared voting power of 2,995,122 shares and shared dispositive power of 3,055,374
shares. The securities as to which the Schedule was filed by Wellington Management Group LLP, as parent holding company of certain holding
companies and the Wellington Investment Advisers, are owned of record by clients of the following entities (collectively, "Wellington Investment
Advisers"): Wellington Management Company LLP; Wellington Management Canada LLC; Wellington Management Singapore Pte Ltd; Wellington
Management Hong Kong Ltd; Wellington Management International Ltd; Wellington Management Japan Pte Ltd; and Wellington Management
Australia Pty Ltd. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global
Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP.
Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
Includes: (i) 400,000 shares subject to options exercisable within 60 days of March 2, 2020 and (ii) 168,000 long-term performance contingent restricted share awards (the "Five-Year Performance RSAs") with respect to which Mr. Winningham has sole voting power but no dispositive power.

Includes 59,375 shares subject to options exercisable within 60 days of March 2, 2020.

Includes: (i) 170,000 shares subject to options exercisable within 60 days of March 2, 2020 and (ii) 54,000 Five-Year Performance RSAs with respect to which Mr. Shafer has sole voting power but no dispositive power.

Includes: (i) 100,000 shares subject to options exercisable within 60 days of March 2, 2020 and (ii) 54,000 Five-Year Performance RSAs with respect to which Mr. Shafer has sole voting power but no dispositive power.

Includes: (i) 36,000 shares subject to options exercisable within 60 days of March 2, 2020 and (ii) 8,385 RSUs subject to release within 60 days of March 2, 2020.

Includes: (i) 36,000 shares subject to options exercisable within 60 days of March 2, 2020 and (ii) 8,385 RSUs subject to release within 60 days of March 2, 2020.

Includes: (i) 24,000 shares subject to options exercisable within 60 days of March 2, 2020 and (ii) 8,385 RSUs subject to release within 60 days of March 2, 2020.

Includes: (i) 24,000 shares subject to options exercisable within 60 days of March 2, 2020 and (ii) 8,385 RSUs subject to release within 60 days of March 2, 2020.

Includes: (i) 36,000 shares subject to options exercisable within 60 days of March 2, 2020 and (ii) 8,385 RSUs subject to release within 60 days of March 2, 2020.

Includes: (i) 25,500 shares subject to options exercisable within 60 days of March 2, 2020 and (ii) 8,385 RSUs subject to release within 60 days of March 2, 2020.

Includes: (i) 24,000 shares subject to options exercisable within 60 days of March 2, 2020 and (ii) 8,385 RSUs subject to release within 60 days of March 2, 2020.

Includes: (i) 36,000 shares subject to options exercisable within 60 days of March 2, 2020 and (ii) 8,385 RSUs subject to release within 60 days of March 2, 2020.

Includes: (i) 36,000 shares subject to options exercisable within 60 days of March 2, 2020 and (ii) 8,385 RSUs subject to release within 60 days of March 2, 2020.

Includes: (i) 36,000 shares subject to options exercisable within 60 days of March 2, 2020 and (ii) 8,385 RSUs subject to release within 60 days of March 2, 2020.

As of December 31, 2019.

Includes an aggregate of (i) 1,108,729 shares subject to options exercisable within 60 days of March 2, 2020; (ii) 83,850 RSUs subject to release within 60 days of March 2, 2020; and (iii) 384,000 Five-Year Performance RSAs with respect to which the holders have sole voting power but no dispositive power.
The following table provides information as of December 31, 2019 with respect to our ordinary shares that may be issued under our existing equity compensation plans.

<table>
<thead>
<tr>
<th>Plan Category</th>
<th>Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights</th>
<th>Weighted Average Exercise Price of Outstanding Options, Warrants and Rights ($)</th>
<th>Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equity compensation plans approved by shareholders</td>
<td>7,617,309(1)</td>
<td>25.48(3)</td>
<td>5,505,307(4)(5)</td>
</tr>
<tr>
<td>Equity compensation plans not approved by shareholders</td>
<td>272,937(2)</td>
<td>17.58</td>
<td>200,261</td>
</tr>
<tr>
<td>Total</td>
<td>7,890,246</td>
<td>24.74</td>
<td>5,705,568</td>
</tr>
</tbody>
</table>

(1) Includes 2,677,535 shares issuable upon exercise of outstanding options and 4,939,774 shares issuable upon vesting of outstanding RSUs.

(2) Includes 272,937 shares issuable upon exercise of outstanding options and no outstanding RSUs.

(3) Does not take into account outstanding RSUs as these awards have no exercise price.

(4) Includes 2,036,122 ordinary shares available under our Employee Share Purchase Plan.

(5) On January 1st of each year, commencing on January 1, 2015 and ending on and including January 1, 2023, the number of authorized ordinary shares under our 2013 Equity Incentive Plan automatically increases by a number of ordinary shares equal to the least of (i) 5% of the total number of outstanding ordinary shares on December 31st of the prior year, (ii) 3,428,571 ordinary shares or (iii) a number of ordinary shares determined by our board of directors. On January 1st of each year, commencing on January 1, 2015 and ending on and including January 1, 2033, the number of authorized ordinary shares under our Employee Share Purchase Plan automatically increases by a number of ordinary shares equal to the least of (i) 1% of the total number of outstanding ordinary shares on December 31st of the prior year, (ii) 571,428 ordinary shares or (iii) a number of ordinary shares determined by our board of directors.

The Theravance Biopharma, Inc. 2014 New Employee Equity Incentive Plan ("2014 Plan") is a non-shareholder approved plan, which was adopted by our board of directors on October 22, 2014 and is intended to satisfy the requirements of Nasdaq Listing Rule 5635(c)(4) or any successor thereto. Nonstatutory share options, share appreciation rights, restricted shares and share units may be granted under the 2014 Plan to new employees of Theravance Biopharma. Our board of directors authorized 750,000 of our ordinary shares for issuance under the 2014 Plan. All option grants made pursuant to the plan must have an exercise price per share of no less than 100% of the fair market value per ordinary share on the grant date. Each option or other equity incentive award granted pursuant to the plan will vest in installments over the holder's period of service with us. Additional features of the 2014 Plan are described in Note 11 to our consolidated financial statements in our Annual Report on Form 10-K filed on February 27, 2020.
RELATED PARTY TRANSACTIONS

In addition to the compensation arrangements with our directors and executive officers described elsewhere in this proxy statement, the following is a description of each transaction since January 1, 2019 and each currently proposed transaction in which:

- we have been or are to be a participant;
- the amount involved exceeds or will exceed $120,000; and
- any of our directors, executive officers or holders of more than 5% of our shares, or any immediate family member of or person sharing the household with any of these individuals (other than tenants or employees), had or will have a direct or indirect material interest.

Indemnification Agreements

We have entered into indemnification agreements with each of our directors and executive officers and certain other employees. The indemnification agreements will provide that we indemnify each of our directors, executive officers and such other employees against any and all expenses incurred by that director, executive officer, or other employee because of his or her status as one of our directors, executive officers, or other employees, to the fullest extent permitted by applicable law and our Amended and Restated Memorandum and Articles of Association. In addition, the indemnification agreements provide that, to the fullest extent permitted by the applicable laws, we will advance all expenses incurred by our directors, executive officers and other employees in connection with a legal proceeding.

Legal Services

We have engaged Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (“Gunderson Dettmer”), of which Mr. Gunderson, one of our directors, is a founding partner, as our primary legal counsel. Fees and reimbursable expenses are incurred in the ordinary course of business, and during the year ended December 31, 2019 we paid approximately $400,000 Gunderson Dettmer for legal services. Mr. Gunderson’s interest in these fees is not readily calculable. We believe the services rendered to us by Gunderson Dettmer were on terms comparable to those that could be obtained in arm’s length dealings with an unrelated third party. We expect to continue to retain the services of Gunderson Dettmer in the future.

Review, Approval or Ratification of Transactions with Related Persons

Transactions, arrangements or relationships in which we were, are or will be a participant and the amount involved exceeds $120,000, and in which any related person had, has or will have a direct or indirect material interest are subject to review, approval or ratification by our audit committee or the independent members of our board of directors. Our board of directors has adopted written policies and procedures with respect to related person transactions and our audit committee has the principal responsibility for reviewing related person transactions. In conformance with SEC regulations, these policies and procedures define related persons to include our executive officers, our directors and nominees to become a director of our company, any person who is known to us to be the beneficial owner of more than 5% of any class of our voting securities, any immediate family member of any of the foregoing persons, and any firm, corporation or other entity in which any of the foregoing persons is employed, is a general partner or in which such person has a 5% or greater beneficial ownership interest. As set forth in our policies and procedures, it is our general policy to approve or ratify related person transactions only when the board of directors or a committee of the board of directors determines that the transaction is in, or is not inconsistent with, our and our shareholders’ best interests, including situations where we may obtain products or services of a nature, quantity or quality, or on other terms, that are not readily available from alternative sources or when the transaction is on terms comparable to those that could be obtained in arm’s length dealings with an unrelated third party.
SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section 16(a) of the Securities Exchange Act requires that our executive officers and directors and persons who own more than 10% of our ordinary shares file reports of ownership and changes of ownership with the SEC. Such directors, executive officers and 10% shareholders are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file. We believe that during the fiscal year ended December 31, 2019, our directors, executive officers and greater than 10% shareholders complied with all applicable Section 16(a) filing requirements. In making this statement, we have relied upon a review of the copies of Section 16(a) reports furnished to us and written representations from certain parties that no other reports were due.
The information contained in the following report of Theravance Biopharma's audit committee is not considered to be “soliciting material,” “filed” or incorporated by reference in any past or future filing by Theravance Biopharma under the Securities Exchange Act of 1934 or the Securities Act of 1933 unless and only to the extent that Theravance Biopharma specifically incorporates it by reference.

Role of the Audit Committee

The audit committee operates under a written charter adopted by our board of directors. The audit committee of our board of directors oversees our accounting practices, system of internal controls, audit processes and financial reporting processes. Among other things, our audit committee is responsible for reviewing our disclosure controls and processes, and the adequacy and effectiveness of our internal controls. It also discusses the scope and results of the audit with our independent registered public accounting firm, reviews with our management and our independent registered public accounting firm our interim and year-end operating results and, as appropriate, initiates inquiries into aspects of our financial affairs. Our audit committee is responsible for establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters, and for the confidential, anonymous submission by our employees of concerns regarding questionable accounting or auditing matters. In addition, our audit committee has sole and direct responsibility for the appointment, retention, compensation and oversight of the work of our independent registered public accounting firm, including approving services and fee arrangements. Significant related party transactions will be approved by our audit committee before we enter into them, as required by applicable rules and listing standards. A more detailed description of the functions and responsibilities of the audit committee can be found in Theravance Biopharma's audit committee charter, published on the corporate governance section of Theravance Biopharma's website at www.theravance.com.

The audit committee oversees our financial reporting process on behalf of the board of directors. Management is responsible for our internal controls, financial reporting process, selection of accounting principles, determination of estimates and compliance with laws, regulations and ethical business conduct. Our independent registered public accounting firm is responsible for expressing an opinion as to the conformity of our consolidated financial statements with generally accepted accounting principles.

Review of Audited Financial Statements for the Year ended December 31, 2019

The audit committee has reviewed and discussed with Theravance Biopharma's management and Ernst & Young LLP the audited consolidated financial statements of Theravance Biopharma for the year ended December 31, 2019. The audit committee has also discussed with Ernst & Young LLP the matters required to be discussed by applicable requirements of the Public Company Accounting Oversight Board regarding communications between our independent registered public accounting firm and audit committee.

The audit committee has received and reviewed the written disclosures and the letter from Ernst & Young LLP required by applicable requirements of the Public Company Accounting Oversight Board regarding the independent accountant's communications with the audit committee concerning independence, and has discussed with Ernst & Young LLP its independence from Theravance Biopharma, Inc.

In performing its functions, the audit committee acts in an oversight capacity and necessarily relies on the work and assurances of our management, which has the primary responsibility for financial statements and reports, and of the independent registered public accounting firm, Ernst & Young LLP, who in their report express an opinion on the conformity of our annual financial statements with
accounting principles generally accepted in the United States and the effectiveness of our internal control over financial reporting. It is not the duty of the audit committee to plan or conduct audits, to determine that our financial statements are complete and accurate and are in accordance with generally accepted accounting principles, or to assess or determine the effectiveness of our internal control over financial reporting.

Within this framework, the audit committee has reviewed and discussed with management Theravance Biopharma's audited financial statements as of and for the year ended December 31, 2019 and its internal control over financial reporting. The audit committee has also discussed with the independent registered public accounting firm, Ernst & Young LLP, the matters required to be discussed by Auditing Standard No. 1301, “Communications with Audit Committees,” issued by the Public Company Accounting Oversight Board. In addition, the audit committee has received the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the Public Company Accounting Oversight Board regarding the independent registered public accounting firm's communications with the Audit Committee concerning independence, and has discussed with the independent registered public accounting firm the independent registered public accounting firm's independence.

Based on the review and discussions referred to above, the audit committee recommended to the board of directors that the audited consolidated financial statements be included in Theravance Biopharma's annual report on Form 10-K for the year ended December 31, 2019 for filing with the SEC.

Submitted by the audit committee

Burton G. Malkiel, Ph.D., Chairman
Eran Broshy
Dean J. Mitchell
Donal O'Connor
OTHER MATTERS

We know of no other matters to be submitted at the Annual Meeting. If any other matters properly come before the Annual Meeting, it is the intention of the persons named in the proxy card to vote the shares they represent as recommended by the board of directors.

It is important that your shares be represented at the Annual Meeting, regardless of the number of shares that you hold. You are, therefore, urged to vote at your earliest convenience on the Internet or by telephone as instructed, or by executing and returning a proxy card in the envelope provided.

THE BOARD OF DIRECTORS
March 24, 2020

63
Your vote matters - here's how to vote!

You may vote online or by phone instead of mailing this card. Votes submitted electronically must be received by 11:59 PM, Eastern Time, on April 27, 2020.

- **Online**
  - Go to [www.investorvote.com/TBPH](http://www.investorvote.com/TBPH) or scan the QR code - login details are located in the shaded bar below.

- **Phone**
  - Call toll free 1-800-652-VOTE (8683) within the USA, US territories and Canada

Save paper, time and money! Sign up for electronic delivery at [www.investorvote.com/TBPH](http://www.investorvote.com/TBPH)

Using a **black ink** pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas.

**2020 Annual General Meeting Proxy Card**

**A**

**THIS PROXY WILL BE VOTED AS DIRECTED, OR IF NO DIRECTION IS INDICATED, WILL BE VOTED “FOR” THE ELECTION OF EACH OF THE DIRECTORS AND “FOR” ITEM 2 AND 3.**

1. Election of Directors:
   - 01 - Dean J. Mitchell
   - 02 - George M. Whitesides
   - 03 - William D. Young

2. Ratify the appointment of Ernst & Young LLP as Theravance Biopharma, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2020.

3. Approve a non-binding advisory resolution regarding executive compensation.

**B**

**Authorized Signatures** - This section must be completed for your vote to count. — Date and sign below.

Please sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, corporate officer, trustee, guardian, or custodian, please give full title.

Date (mm/dd/yyyy) — Please print date below. Signature 1 — Please keep signature within the box. Signature 2 — Please keep signature within the box.

Small steps make an impact. Help the environment by consenting to receive electronic delivery, sign up at www.investorvote.com/TBPH.

IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.

Proxy – THER AVANCE BIOPHARMA, INC.

Annual General Meeting of Shareholders – April 28, 2020

THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS OF THE COMPANY

The undersigned hereby appoints Rick E Winningham and Andrew A. Hindman, and each of them, with power to act without the other and with power of substitution, as proxies and attorneys-in-fact and hereby authorizes them to represent and vote, as provided on the other side, all the Ordinary Shares of Theravance Biopharma, Inc. which the undersigned is entitled to vote, and, in their discretion, to vote upon such other business as may properly come before the Annual General Meeting of Shareholders of the company to be held April 28, 2020 or at any adjournment or postponement thereof, with all powers which the undersigned would possess if present at the Meeting.

(Continued and to be marked, dated and signed, on the other side)

Non-Voting Items

Change of Address – Please print new address below. Comments – Please print your comments below.

Authorized Signatures — This section must be completed for your vote to count. — Date and sign below.

THIS PROXY WILL BE VOTED AS DIRECTED, OR IF NO DIRECTION IS INDICATED, WILL BE VOTED “FOR” THE ELECTION OF EACH OF THE 2020 Annual General Meeting Proxy Card.
# 2020 Annual General Meeting Proxy Card

IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.

**A**

<table>
<thead>
<tr>
<th>1. Election of Directors</th>
<th>For</th>
<th>Against</th>
<th>Abstain</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 - Dean J. Mitchell</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02 - George M. Whitesides</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>03 - William D. Young</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. Ratify the appointment of Ernst & Young LLP as Theravance Biopharma, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2020.

3. Approve a non-binding advisory resolution regarding executive compensation.

**B**

Authorized Signatures — This section must be completed for your vote to count. — Date and sign below.

Please sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, corporate officer, trustee, guardian, or custodian, please give full title.

Date (mm/dd/yyyy) — Please print date below.

Signature 1 — Please keep signature within the box.

Signature 2 — Please keep signature within the box.

[Redacted barcodes]

IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. ▼

Proxy – THERAVANCE BIOPHARMA, INC.

Annual General Meeting of Shareholders — April 28, 2020

THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS OF THE COMPANY

The undersigned hereby appoints Rick E Winningham and Andrew A. Hindman, and each of them, with power to act without the other and with power of substitution, as proxies and attorneys-in-fact and hereby authorizes them to represent and vote, as provided on the other side, all the Ordinary Shares of Theravance Biopharma, Inc. which the undersigned is entitled to vote, and, in their discretion, to vote upon such other business as may properly come before the Annual General Meeting of Shareholders of the company to be held April 28, 2020 or at any adjournment or postponement thereof, with all powers which the undersigned would possess if present at the Meeting.

(Continued and to be marked, dated and signed, on the other side)